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Out of the night that covers me, 
Black as the pit from pole to pole, 
I thank whatever gods may be 
For my unconquerable soul. 
 
In the fell clutch of circumstance 
I have not winced nor cried aloud. 
Under the bludgeonings of chance 
My head is bloody, but unbowed. 
 
Beyond this place of wrath and tears 
Looms but the Horror of the shade, 
And yet the menace of the years 
Finds and shall find me unafraid. 
 
It matters not how strait the gate, 
How charged with punishments the scroll. 
I am the master of my fate: 
I am the captain of my soul. 
 
(Traduzione) 
 
Dal profondo della notte che mi avvolge, 
Buia come un pozzo che va da un polo all'altro, 
Ringrazio qualunque dio esista 
Per l'indomabile anima mia. 
 
Nella feroce stretta delle circostanze 
Non mi sono tirato indietro né ho pianto forte. 
Sotto i colpi d’ascia della sorte 
Il mio capo è sanguinante, ma indomito. 
 
Oltre questo luogo d'ira e di lacrime 
Si profila il solo Orrore delle ombre, 
E ancora la minaccia degli anni 
Mi trova e mi troverà senza paura. 
 
Non importa quanto stretto sia il passaggio, 
Quanto piena di castighi la vita, 
Io sono il padrone del mio destino: 
Io sono il capitano della mia anima. 
 
Invictus (W. E. Henley 1849-1903) 
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Abstract 
 
The reconstruction of the regulatory interactions among DNA, RNAs and proteins in a cell is probably the 
most important and key challenge in molecular biology. In the last decade, the introductions of new 
high-throughput technologies, such as microarrays and, more recently, next generation sequencing 
(NGS) have facilitated this task. Different Systems Biology approaches have been proposed to 
reconstruct the transcriptional, post-transcriptional and the post-translational regulatory networks of a 
cell starting from genomics data. The two aims of the research here described are: (1) the development 
and the application of a computational method for the identification of tissue-specific, or more broadly, 
condition-specific pathways; (2) the development and the application of a computational approach for 
the identification of post-translational modulators of transcription factor activity from gene expression 
profiles. 
In Chapter 1, I provide a brief overview of the different molecular networks known to exist in a 
living cell. Chapter 2 illustrates a comparative study of the different approaches to reverse-engineering 
gene networks from gene expression profiles (GEPs) and their limitations. Current state-of-the-art 
reverse-engineering approaches model gene networks as static processes, i.e. regulatory interactions 
among genes in the network (such as direct physical interactions or indirect functional interactions) do 
not change across different conditions or tissue types. However, different cell-types, or the same cell-
type but in different conditions, may carry out very different functions, thus it is expected that their 
regulatory networks may reflect these differences. 
In Chapter 3 and 4, I describe the development of a novel approach named DINA (Differential 
Network Analysis) for the identification of differentially co-regulated pathways. DINA is based on the 
hypothesis that genes belonging to a condition-specific pathway are actively co-regulated only when the 
pathway is active, independently of their absolute level of expression. I first reverse-engineered 30 
tissue-specific networks from a collection of about 3000 GEPs. I then applied DINA to these networks in 
order to identify tissue-specific pathways starting from a list of 110 KEGG-annotated pathways. As 
expected, DINA predicted many metabolic pathways to be tissue-specific and prevalently active in liver 
and kidney. I then built a simplified model of hepatocellular carcinoma (HCC) to mimic the HCC 
progression using three condition-specific regulatory networks obtained from three different cell-lines: 
(i) primary hepatocyte, (ii) HepG2 and (iii) Huh7. Using these three cell-type specific networks, I 
demonstrated that DINA can be used to make hypotheses on dysregulated pathways during disease 
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progression. DINA is also able to predict which Transcription Factors (TFs) may be responsible for the 
pathway condition-specific co-regulation. I tested this approach to identify regulators of tissue-specific 
metabolic pathways, and I correctly identified Nuclear Receptors as their main regulators. With this 
method, I was also able to identify a new putative tissue-specific negative regulator of hepatocyte 
metabolism: Yeats2. 
In Chapter 5, 6 and 7, I propose a generalized method that I called Differential Multi-Information 
(DMI) to identify post-translational modulators  of a transcription factor    by observing the changes 
in co-regulation (measured by Multi-Information) among a set of n target genes       in the presence 
or absence of the modulator . My working hypothesis is that the set of target genes will be strongly 
co-regulated only when the modulator   is present, since the modulator will active the   . The DMI 
algorithm requires in input a set of known target genes regulated by a common   , and it returns in 
output a ranked list of predicted post-translational modulators of the   . I first validated the approach 
using an “in-silico” datasets consisting of 100 GEPs and 760 genes. Next, I tested DMI performance on a 
real gene expression profile dataset, by identifying the post-translational modulators of 7 transcription 
factors for which I was able to collect a list of high-confident targets. This set of transcription factors 
included transcription factors  such as P53, MYC and STAT3. Finally, as a case of study, I tested the DMI 
method on a transcription factor TFEB recently identified as a master regulator of lysosomal biogenesis 
and autophagy. By comparing the results of DMI with a High Content Screening (HCS) using siRNA oligo 
libraries against all the known phosphatases, I was able to show that DMI can achieve a very high 
precision. All these results confirm that DMI could be instrumental in identifying post-translational 
regulatory interactions in an efficient and cost-effective manner. 
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Chapter 1 
Introduction to regulatory networks 
Interactions among molecules in a cell lead to a complex regulatory network, which is only partially 
understood. Biological networks are regulated at many levels by different kinds of mechanisms. For the 
sake of simplicity, here I will consider only three types of regulations that can occur in a cell and thus 
three types of regulatory networks: (i) transcriptional regulatory networks describing transcriptional 
regulations such as protein-DNA interactions; (ii) post-transcriptional regulatory networks where post-
transcriptional regulations occurs at the RNA  level before its eventual translation; (iii) post-translational 
regulatory networks where post post-translational regulations occurs at the protein level, i.e. a protein 
covalently modified “on the fly”. In this Chapter, I will give a brief introduction on each one of these 
three types of regulations and their regulatory networks. 
 
 
1.1 Transcriptional Regulation 
In eukaryotic organisms protein-coding gene expression is promoted by RNA polymerase II and it can be 
regulated at several steps, including transcription initiation and elongation, and mRNA processing [1].  
Genes that are transcribed by the RNA polymerase II usually contain two distinct families of cis-acting 
transcriptional regulatory DNA elements: (a) a promoter region located near the gene, which structure 
can be quite complex containing many specific DNA sequences and response elements that provide a 
secure initial binding site for RNA polymerase and the other proteins required for the transcription, and 
(b) distal regulatory elements, which can be enhancers, silencers, insulators, or locus control regions 
(LCR). In particular, these cis-acting transcriptional regulatory elements contain recognition sites for 
trans-acting DNA-binding transcription factors, which function either to enhance or repress transcription 
[1]. 
The factors that are involved in the transcription of eukaryotic protein-coding genes by RNA 
polymerase II can be categorized into three distinct groups: (i) general (or basic) transcription factors 
(GTFs), (ii) promoter-specific activator proteins (activators or transcription factors), and (iii) coactivators 
(Figure 1). Moreover, the existence of multiple regulatory elements on the promoter regions of a 
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protein-coding gene lead to a combinatorial control of regulation, with a consequential exponentially 
increases for the potential number of unique expression patterns. 
 
 
Figure 1 – Simplified diagram of transcriptional regulations (source Wikipedia). 
 
 
As shown in Figure 2, the transcriptional machinery start assembling GTFs to form a transcription pre-
initiation complex (PIC), this complex is useful to direct RNA polymerase II to the transcription start site 
(TSS). In particular, the first step in PIC assembly is binding of TFIID, a multi-subunit complex consisting 
of TATA-box-binding protein (TBP) and a set of tightly bound TBP- associated factors (TAFs). Then, many 
other steps are required before the transcription of a gene starts and, in particular, before that a fully 
functional RNA polymerase II elongation complex is formed [1]. 
The only assembly of a PIC on the core promoter is not sufficient to have a functional 
transcriptional machinery, but it is sufficient to direct only low levels of accurately initiated transcription 
from DNA templates in vitro. This process is generally referred to as basal transcription. Transcriptional 
activity is greatly stimulated by a second class of factors, termed activators. These activators, in general, 
are sequence-specific DNA-binding proteins able to recognize specific sequence to bind on the core 
promoter. In the last decade, different classes of activators, discriminated by different DNA-binding 
domains, have been discovered, each one associated with their own class of specific DNA sequences [1]. 
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The DNA-binding sites for activators are also called transcription factor-binding sites (TFBSs). These sites 
are generally very small, consisting of 6–12 bp, although the binding specificity of an activator is usually 
stated by no more than 4–6 nucleotides (i.e. consensus sequence) within the site. For this reason the 
TFBSs for a specific activator is typically described by this consensus sequence for which an activator is 
relatively constrained, while the other nucleotides can vary. The particular sequence of a TFBS is 
fundamental, and it can also affect the structure of a bound activator in a way that alters its activity [1]. 
Finally, activators have also been proposed to function by recruiting activities that modify 
chromatin structure [2, 3]. Chromatin barrier can prevent the transcriptional machinery from interacting 
directly with promoter DNA and thus preventing activator binding and PIC assembly. 
Although the phenomenon of transcriptional synergy has long been recognized, the mechanism 
underlying it has remained sill elusive and needs to be still studied. 
 
 
 
Figure 2 – Cartoon schema of the eukaryotic transcriptional machinery. Factors involved in eukaryotic transcription by RNA 
polymerase II can be classified into three groups: general transcription factors (GTFs), activators, and coactivators. In addition 
to the RNA polymerase II, the class of GTFs includes TFIIA, TFIIB, TFIID, TFIIE, TFIIF, and TFIIH. These proteins are assembled on 
the core promoter in order to form a pre-initiation complex (PIC), able to direct the RNA polymerase II on the transcription start 
site (TSS). Transcriptional activity is then promoted by other activators proteins (i.e. transcription factors), which bind specific 
areas of the promoter region and work stimulating PIC formation. Two parts principally compose activators: (i) DNA-binding 
domain (DBD) and (ii) a separable activation domain (AD) that is required for the activator to stimulate transcription. (Figure 
taken from the review work of Glenn et al. “Transcriptional Regulatory Elements in the Human Genome” [1]) 
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1.2 Post-transcriptional regulation 
Post-transcriptional regulation of gene expression performs an important role in many cellular processes 
including cell development, metabolism and cancer progression. In the recent years the discovery of the 
role of microRNAs (miRNAs) as keys molecules of post-transcriptional regulators of gene expression has 
emerged [4]. MicroRNAs are a large family of small, approximately 21-nucleotide-long, non-coding RNAs 
(Figure 3). In particular, miRNAs are able to modulate gene expression at post-transcriptional level 
regulating mRNA translation or stability in the cytoplasm [5-8]. It has been estimated that miRNAs may 
regulate about 30% of all protein-coding genes [4]. 
 
 
 
Figure 3 – Simplified diagram of microRNA (source Wikipedia). 
 
 
As shown in Figure 4 microRNAs are processed from precursor molecules called pre-miRNAs, which can 
be either transcribed by RNA polymerase II from transcripts belonging portions of non-coding genes 
(exons) or portions of introns. A single pre-miRNA usually contains sequences for many different 
miRNAs. After its transcription, pre-miRNAs fold into hairpin structures containing imperfectly base-
19 
 
paired stems. Then they are processed in two steps, catalysed by the RNase III type endonucleases 
Drosha (also known as RN3) and Dicer [4]. 
In animals, pre-miRNAs are transported to the cytoplasm by exportin5 protein, where they are 
thus cleaved by Dicer to yield about 20-bp miRNA duplexes. After this step, usually only one strand is 
then selected to function as a mature miRNA, while the other strand is degraded. Only occasionally, 
both arms of the pre-miRNA hairpin give rise to mature miRNAs [4]. 
During their processing, miRNAs are assembled into ribonucleoprotein (RNP) complexes called 
micro-RNPs (miRNPs) or miRNA-induced silencing complexes (miRISCs). Anyway, the assembly process 
of miRNA is a dynamic process, for which many details are still not well understood. The keys 
components of miRNPs are proteins of the Argonaute (AGO) family. In mammals, four AGO proteins 
(AGO1 to AGO4) are involved in miRNA pathway, but only AGO2 functions in RNAi, while the other three 
are involved in the miRNA repression. In particular, AGO2 seems to be involved first in the cleavage of 
the passenger (or sense) strand of the double-stranded siRNA, thus forming the single-stranded RNA 
that is used by the RISC complex as the guide strand to bind the target mRNA; then RISC can undergo 
multiple rounds of mRNA cleavage, mediating a robust silencing effect on the target gene. Apart from 
AGOs, miRNPs can contain further proteins that function as regulatory factors or effectors mediating 
inhibitory function of miRNPs (for more details on the production of miRNAs, refer to Box 1 in [4]). 
With few exceptions, miRNA-binding sites in metazoan mRNAs lie in the 3’ UTR and usually 
multiple copies are required for effective repression of target genes [9-13]. However, in many cases, 
miRNAs pair imperfectly with their RNA targets, following a set of rules determined by experimental and 
bioinformatics analyses [9-13].  
In addition to miRNA many other classes of non-coding RNAs have been, and are being, 
discovered but since these have no direct relevance to this thesis, I will not mention them in this 
Chpater. 
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Figure 4 – The biogenesis of miroRNAs and their assembly into microribonucleoproteins (Figure taken from the review work of 
Filipowicz et al. “Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight?” [4]). 
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1.3 Post-translation regulation 
The discovery that the human genome is composed only by about 20,000 genes [14] has stressed the 
complexity and the importance of regulation of gene expression and protein activity. Whereas 
Transcription Factors and noncoding RNA have a predominant role in regulation of gene expression, 
other proteins, such as kinases and phosphatases, control protein activation via post-translational 
modifications (PTMs). A post-translational modification is a chemical mechanism in which amino-acid 
residues in a protein are covalently modified “on the fly”. Through this mechanism a cell is able to tightly 
regulate its functions regulating the activity, localization and interaction of many molecules including 
proteins, nucleic acids, lipids, and cofactors [15].  
A simple example of PTM-mediated information processing can be found in reversible 
phosphorylation on a single site (Figure 5), where a single residue on a substrate can be dynamically 
regulated through phosphorylation or dephosphorylation. Hence, phosphorylation is a binary 
modification, where a given serine, threonine or tyrosine residue is either phosphorylated or not. Since 
a protein has in general   sites of phosphorylation then the total number of possible states is 
combinatorial and in particular equal to   . This, obviously considering the simplest case in which each 
site can have only   modification, but in general the situation is more complex since a single site can 
also has   associated modifications. 
Post-translational modification can occur at any step in the life of a protein. Many proteins are 
modified shortly after translation to regulate the folding, the stability or to direct sign a protein that 
must be translocated in another compartment of the cell as membrane, cytoplasm and so on. Other 
modifications instead can occur after the folding and the localization in order to influence the biological 
activity of the protein as for example occur for many transcription factors. 
In addition to phosphorylation events many other kinds of post-translational modifications can 
occur, including glycosylation, ubiquitination, nitrosylation, methylation, acetylation and lipidation [15]. 
Protein glycosylation is considered one of the major post-translational modifications, with significant 
effects on protein folding, conformation, distribution, stability and activity. Ubiquitination is a PTM 
useful to mark a protein, which must be degraded by the proteasome machinery. Ubiquitin is an 8-kDa 
polypeptide consisting of 76 amino acids that is appended to the protein. Nitrosylation is a reversible 
reaction and a critical PTM used by cells to stabilize proteins and regulate gene expression, by providing 
nitric oxide (NO). Methylation consists in the addition of a methyl group to a substrate or the 
substitution of an atom or group by a methyl group. This kind of PTM contributes to epigenetic 
22 
 
inheritance by, for example, modifying histone tails, but it can occur also at the DNA level (DNA 
methylation). Amino acid residues can be conjugated to a single methyl group or multiple methyl groups 
to increase the effects of modification. Acetylation is the transfer of an acetyl group to nitrogen and it 
occurs in almost all eukaryotic proteins through both irreversible and reversible mechanisms. It is a 
common method of regulating gene transcription. For example histone acetylation is a reversible event 
used by the cell to reduce the chromosomal condensation and thus to promote the transcription. 
Usually, the acetylation of these lysine residues is regulated by transcription factors containing histone 
acetyletransferase (HAT) activity. While transcription factors with HAT activity act as transcription co-
activators, histone deacetylase (HDAC) enzymes are co-repressors that reverse the effects of acetylation 
by reducing the level of lysine acetylation and increasing chromosomal condensation. Lipidation is PTM 
used to target proteins to membranes in organelles including endoplasmic reticulum (ER), Golgi 
apparatus, mitochondria, vesicles (endosomes, lysosomes) and the plasma membrane. 
 
 
 
Figure 5 – Example of reversible phosphorylation. A single site is dynamically regulated adding a phosphate group by a forward 
kinase and removing a phosphate group by a reverse phosphatase. 
 
 
 
 
23 
 
1.4 Conclusion and open challenges 
Following the completion of the human genome sequence draft in 2000, more than 20,000 protein-
coding genes were identified and annotated [14]. Once this first milestone had been achieved, the nest 
and key challenge was elucidate the regulatory networks controlling expression of these genes in a 
condition-specific, cell-specific and tissue-specific manner. To explain the molecular mechanisms behind 
these specific cellular expression patterns, it is fundamental to identify the specific transcriptional 
regulatory sequences, such as transcription factor binding sites, associated with each one of the 
predicted genes, and PTM regulating transcription factor activity. Indeed in a cell thousands of 
molecules interact with each other in a complex regulatory network (Figure 6). Moreover, this network 
changes its behaviour dynamically since it is subjected also to external stimuli.  
The advent of high-throughput technologies, such as microarrays and Next Generation 
Sequencing (NGS) based approaches, has facilitated this task. These high-throughput data are an 
extremely useful resource for the study of transcription regulation. High-throughput techniques provide 
genome-wide information regarding the establishment of spatial and temporal gene expression patterns 
and the mechanisms required for their establishment. In order to extract biological useful information 
from these data and to make evidence-based hypotheses on regulatory mechanisms active in the cell, it 
is essential to develop new computational “reverse-engineering” methods (refer to Chapter 2).  The 
challenge for Systems Biology and in particular for reverse engineering is to infer gene networks, 
transforming high-throughput heterogeneous data sets into biological insights about the underlying 
mechanisms. 
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Figure 6 – A simplified example of regulatory networks in a cell. For simplicity we considered only four regulatory networks: (i) 
the transcriptional regulatory network where interaction among transcript are described; (ii) the microRNA regulatory network 
where microRNA interactions are reported; (iii) the protein regulatory network containing interactions among proteins, 
including post-translational interactions; (iv) the metabolic regulatory network where relationship among metabolites are 
reported. Obviously, all these regulatory networks are part of a single regulatory network in a cell, since the elements of these 
networks are interconnected. Consider, for example, the orange gene encoding for an orange enzyme able to catalyse a 
metabolic reaction, whose en product acts as a signal for a green kinase, which in turn activates a blue transcription factor. 
Finally, one of the downstream targets the blue transcription factor contain a yellow microRNA used to interfere the production 
of the orange protein. 
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Chapter 2 
Introduction to reverse-engineering 
With the diffusion of high-throughput technologies such as microarrays and more recently Next 
Generation Sequencing, massive genome-wide datasets measuring gene expression, and other relevant 
biological information, have been produced. For this reason in the last decade, new computational 
techniques for the analysis of these high-dimensional data have been developed giving rise to the 
interdisciplinary field of computational Systems Biology. In this chapter, I will introduce the main state-
of-the-art reverse-engineering approaches for the reconstruction of gene regulatory network from gene 
expression profiles.  
 
2.1 Introduction 
As anticipated in the conclusion of the previous chapter, in the last decade, reverse-engineering 
techniques have been mainly focused on inferring transcriptional regulatory networks. The reason for 
this can be found in the diffusion of DNA microarray technology. This technology has enabled 
researchers to efficiently measure the concentration of all RNA transcripts in a cell with a relative low 
cost. On the contrary, measuring the concentration of others molecules in the cell, including proteins 
and metabolites, is generally more difficult, and hence such data are not abundant in the literature. 
Reverse-engineering techniques can be principally divided in two classes: “physical” and 
“influence" approaches. A physical approach seeks to identify the protein factors that regulate 
transcription, and the DNA motifs on the promoter regions where these factors bind. With this 
technique, it is possible reduce the dimensionality of the reverse-engineering problem, since the 
“actors” to identify are reduced only to the TFs present in the genome. The second class, which we call 
the “influence” approach, seeks to reconstruct the relationship among RNA transcripts. Such model 
does not generally describe physical interactions between molecules since transcription is rarely 
controlled directly by RNAs, but with this approach it is possible to implicitly capture regulatory 
mechanisms at the protein and metabolite level that are not directly measured. Hence “influence” 
approaches are not restricted to describing only transcription factor/DNA interactions, but also indirect 
interactions occurring among genes via proteins, metabolites and non-coding RNAs that have not been 
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measured directly. The concept of influence interaction is not well defined and it is strongly dependent 
on the mathematical formalism used by the reverse-engineering method. Therefore, to avoid confusion, 
here I will refer to functional interactions by the term “connection”, whereas the term “interaction” will 
be used only when a physical interaction between the DNA, RNA or protein products of the genes is 
occurring [16]. 
Methods to infer a gene regulatory network rely on the analysis of the transcriptional response 
of a population of cells to multiple experimental conditions. High-throughput technologies such as 
microarray and more recently next generation sequencing allow measuring genome-wide expression 
under specific experimental conditions. The capability to “obtain” the fingerprint of a cell at a specific 
time and condition, together with the large number of expression data now available allow to use 
methods from engineering mathematics and statistics to explore and analyse gene expression data 
An inferred gene network is therefore a collection of gene-gene connections (or TF-gene 
interactions) captured from expression data. A gene network is not only able to store information 
regarding the relationship among the transcripts but it also contains much more information that can be 
used to study the behaviour of a cell such as for example the topological organization of its nodes 
(genes). A community in a network of genes, for example, identifies a group of genes that are highly 
connected among them and sparsely connected with genes outside the group. These communities can 
be used to detect the functional modules in the cell, that is, groups of genes cooperate to accomplish 
specific functions. 
In this chapter, I will present different approaches to infer or “reverse-engineer” influence gene 
regulatory networks from gene expression profiles measured by microarray technology. A description of 
other methods based on the physical approach and more details on computational aspects can be found 
in [17-22]. From an engineering point of view, knowledge of how gene expressions change following the 
perturbation experiment allows to identify the network of regulatory interactions occurring among 
them. This identification process can take different names depending on the field of application, such as: 
system identification and reverse-engineering. 
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2.2 Microarray technology and microarray data repositories  
A DNA microarray (DNA chip) is a collection of small DNA oligomers laying on a solid surface of 
approximately 1 or 2 cm (chip). DNA oligomers on the chip are organized in approximately 250,000 
“spots” (depending on the chip model), and each spot contains millions of copy of the same DNA 
sequence, called probe. Microarrays allow to simultaneously measuring the expression of thousands of 
genes starting from total RNA extracted from a cell population. 
When samples are prepared, in the first step the total RNA is converted into cDNA through 
reverse transcriptase and then it is tagged with a ﬂuorescent marker. Finally, cDNA is placed on the 
microarray chip and the complementarity between two fragments allows the hybridization of a cDNA 
sequence on the corresponding DNA “spot”. The number of hybridized probes in a spot and the 
expression level of the gene are directly related. Hence, with microarray technology the expression level 
of a gene is quantiﬁed through ﬂuorescence analysis.  
There exist different types of microarrays, but we can divide they in two main categories:: (i) 
two channels microarrays and (ii) one channel microarrays. The main difference is that with two 
channels microarrays concurrently measure on the same chip the gene expression levels of treated cells 
and control cells. 
Moreover there exist other types of microarray that can be used to measure single nucleotide 
polymorphism, fusion genes, alternative splicing, and so on. Here, we concentrate on DNA single 
channel microarrays and we use the term hybridization and gene expression proﬁle (GEP) to refer to a 
set of gene expression levels collected on a single microarray chip. Moreover, we will refer to a set of 
hybridizations with the term experiment. 
The ﬂuorescence levels collected from microarray hybridization are called raw data. The 
hybridizations in the same experiment are usually “normalized” where noise is removed, the 
background ﬂuorescence is subtracted and the average ﬂuorescence level among the spots associated 
to the same probe is computed. The output of this normalization step yields a set of comparable gene 
expression proﬁles. We refer to a set of normalized GEPs (or experiment) with the term processed GEPs. 
Two major GEPs public repositories exists: the Gene Expression Omibus (GEO [23]) and Array 
Express [24]. In both repositories, GEPs are logically divided into experiments (i.e. a collection of GEPs 
usually performed in a single laboratory).  Still in both repositories GEPs are stored with their 
METADATA useful to trace different kinds of information including the experimental protocol used, the 
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type of samples (i.e. cell types or tissues), and many other information that the MIAME standard [25] 
requires. Obviously they periodically mirror their experiments. 
 
 
2.3 Reverse-engineering transcriptional networks: methods and 
applications 
 
2.2.1 Bayesian networks 
Deﬁnition: A Bayesian Network (BN) is a Directed Acyclic Graph (DAG)          together with a set of 
local probability distributions  . The vertices   corresponds to variables, and the arcs or edges   
represent probabilistic dependency between the variables. An arc from variable   to variable   states a 
probabilistic dependence between the two variables, i.e. the state of Y depends on the state of  . In this 
case,   is called a parent of  . A node with no parents is unconditional.   contains the local probability 
distributions of each node   conditioned on its parents. 
 
Bayesian Networks give a graphical representation of probabilistic relationships among a set of random 
discrete or continuous variables   , with          . An example of Bayesian network is provided in 
(Figure 7). One of the main properties of BNs is their ability to handle incomplete data sets and their 
robustness to noise that is typical of biological experiments. This last property is a consequence of the 
robustness of the statistical model that they adopt. Since these advantages, many researchers, in the 
last years have devoted considerable attention in the use of Bayesian network approaches for reverse-
engineering gene networks [26-33]. 
Bayesian networks are able to describe the relationship between variables at both qualitative 
and quantitative level. At a qualitative level, the relationships between variables    are relations of 
dependence and conditional independence represented as directed graph  . More precisely vertices of 
the graph   correspond to variables and a direct edge between a pair of vertices represents 
dependencies between the two variables. 
29 
 
At a quantitative level instead, relations between variables are described by a family of joint probability 
distributions               that are consistent with the independence assertions embedded in the 
graph   and it has the form: 
 
               ∏        |                  
 
             (2.1) 
 
where the       genes on which the probability is conditioned are called the parents of gene   and 
represent its regulators, and the joint probability density is expressed as a product of conditional 
probabilities by applying the chain rule of probabilities and independence. This rule is based on the 
Bayes theorem: 
 
            |             |              (2.2) 
 
The JPD (joint probabilty distribution) can be decomposed as the product of conditional probabilities as 
in Eq. 2.1 only if the Markov assumption holds, i.e. each variable    is independent of its non-
descendants, given its parents in the directed acyclic graph  . A schematic overview of the theory 
underlying Bayesian networks is given in Figure 7. 
The joint probability distribution,         , for the Bayesian network in Figure 7 is given by 
 
                |      |       |        |         |           (2.3) 
 
In order to reverse engineer a gene network using a Bayesian network model, two sets of parameters 
have to be estimated: (i) the conditional probability functions relating the state of the regulators to the 
state of the transcripts and (ii) the directed acyclic graph   (i.e. the regulators of each transcript) that 
“best” describes the gene expression data D, where D is assumed to be a steady-state data set. The 
model-learning algorithm usually assumes a speciﬁc form of the conditional probability function. 
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Figure 7 - Systematic overview of the theory underlying diﬀerent models for inferring gene regulatory networks. Bayesian 
networks: A is conditionally independent from D and E given B and C; Information-Theoretic networks: Mutual information is 0 
for statistically independent variables, and Data Processing Inequality helps pruning the network; Ordinary Diﬀerential 
Equations: Deterministic approach where the rate of transcription of gene A is a function (f) of the level of its direct causal 
regulators. (Figure taken from Bansal et al. “How to infer gene networks from expression profiles” [16]) 
 
 
The network structure is usually determined using a heuristic search due the NP-hard complexity of the 
problem. Many heuristics can be used, including greedy-hill climbing approach, Markov Chain Monte 
Carlo method or simulated annealing. For each network structure   visited in the search, the algorithm 
learns the maximum likelihood parameters for the conditional probability functions. It then computes a 
score that evaluates each graph   (i.e. a possible network topology) with respect to the gene expression 
data D. The score can be deﬁned using Bayes rule: 
 
   |   
   |      
    
         (2.4) 
 
where      can either contain some a priori knowledge on network structure, if available, or can 
be a constant non-informative prior, and     |    is a function, to be chosen by the algorithm, that 
evaluates the probability that the data D has been generated by the graph  . The most popular 
scores are the Bayesian Information Criteria (BIC) and the Bayesian Dirichlet equivalence (BDe). 
Both scores incorporate a penalty for complexity to guard against over ﬁtting of data. 
In Bayesian networks, the learning problem is usually underdetermined and several high 
scoring networks are found. A possible solution consists to use model averaging or bootstrapping to 
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select the most probable regulatory connection and to obtain conﬁdence estimates for the 
connection. 
But the main limitation of Bayesian networks remains that they assume the acyclic structure 
of the network (i.e. no feedback loops). Dynamic Bayesian networks [34-36] overcome this 
limitation and can be used to infer cyclic phenomena such as feedback loops that are prevalent in 
biological systems and they are also able to infer interactions from a time-series dataset.  
 
 
2.2.2 Associative Networks 
Associative networks are used to represent pairs of transcripts that coherently change their expression 
levels across a set of different conditions (i.e. co-expressed genes). Association networks connect 
transcripts that exhibit high statistical dependence by observing changes in their responses across all the 
experiments in the dataset. As a measure of similarity the pair-wise correlation (Pearson or Spearman) is 
often used.  The Person correlation coefficient is computed as: 
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   ∑      ̅ 
  
   
             
 
The Spearman correlation coefficient between pair of transcript   and   is computed instead as: 
 
      
 ∑  
 
       
              
 
where          is the difference between the ranks of each observation on the two variables are 
calculated.  
Since many false positive connections are usually identified using these techniques, a pruning 
process can be undertaken to remove connections that are better explained by a more direct path 
through the graph. In [35] de la Fuente et al. proposed the application of partial correlation to prune the 
network and to remove redundant connections. Briefly, partial correlation measures the correlation 
between two variables after subtracting the correlation between each variable and one or more 
additional variables. 
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Correlation based methods are able to identify only linear dependencies between two variables. 
Mutual information instead makes no assumptions about the form of the dependence and in particular 
it is able to discover also nonlinear relationships among variables. Regarding association networks based 
on Mutual Information, let us consider a variable   with   possible states,       each with its 
corresponding probability      . The average amount of information gained from a measurement that 
speciﬁes one particular value    is given by entropy     and is computed as: 
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The entropy     has the following four properties:  
 
1. If an outcome of the measurement is completely determined by    i.e. the probability 
      is one and all other probabilities       with     are zero, then      . 
2. For equiprobable events the entropy     is maximum and is given by: 
 
      
 
 
                          
 
3. Entropy remains unchanged when impossible events are added. 
4. If the logarithm to base   is used, the entropy is normalized (i.e.         ) 
 
The joint entropy        of two discrete variables   and  , with   assuming values in the set {     }, 
is given by:  
 
        ∑∑ (     )     (     )
 
   
 
   
                
 
 (     ) denotes the joint probability that   is in state    and   in state   . If the systems   and   are 
statistically independent the joint probability factorize and the joint entropy       becomes: 
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The mutual information        or     between variables   and   is deﬁned as:  
 
                                          
 
There exist two main strategies to estimate mutual information: (i) histogram techniques and (ii) kernel 
density approach. There are many algorithms that have successfully applied the association network 
based on MI [37, 38] and shown its application in biological systems. 
The definition of MI requires each data point (i.e. each experiment) to be statistically 
independent from the others. Thus information-theoretic approaches, as described here, can deal with 
steady-state gene expression dataset, or with time-series data as long as the sampling time is long 
enough to assume that each point is independent. 
Edges in networks derived by information-theoretic approaches represent statistical 
dependences among gene expression profiles. As in the case of Bayesian network, the edge does not 
represent a direct causal interaction between two genes, but only a statistical dependency. 
Theoretically, the main difference between MI and Pearson correlation coefficient is that MI can 
quantify also nonlinear dependencies between variables meaning that zero value of correlation cannot 
imply that two variables are statistically independent. 
 
 
2.2.3 Ordinary differential equations (ODEs) 
Reverse-engineering algorithms based on Ordinary Diﬀerential Equations (ODEs) [22, 39-41] relate 
changes in gene transcript concentration in a system subject to an external perturbation. Where by 
external perturbation I mean an experimental treatment (i.e. small molecules inducing overexpression 
or down regulation of other genes) that can alter the transcription rate of some of the genes in the cell. 
ODEs are a deterministic approach unlike Bayesian networks and association network approaches. A set 
of ordinary diﬀerential equations, one for each gene, describes the gene regulation as a function of 
other genes: 
 
 ̇                                    
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where    is a set of parameters describing interactions among genes (the edges of the graph), 
          and       is the concentration of transcript   measured at time  ,  ̇     is the rate of 
transcription of transcript  ,   is the number of genes, and   is an external perturbation to the system. 
Since ODEs are deterministic, the interactions among genes (  ) represent causal interactions, and not 
statistical dependencies as the other methods. 
The functional form of the inﬂuence functions    can be either linear of nonlinear, nonlinear 
functions can lead to an exponential rise in the unknown parameters to be estimated. Researchers have 
studied various functions, including sigmoidal functions [42], linear [22, 43, 44] and non-linear [45] 
functions. 
Reverse-engineer a network using ODEs means to choose a functional form for   and then to 
estimate the unknown parameters    for each i from the gene expression data D using some 
optimization technique.  
The easiest form that this function can assume is the linear form where Equation 2.12 becomes:  
 
 ̇     ∑        
 
              
 
where     represents the inﬂuence of transcript   on transcript   and    is an externally applied 
perturbation to the level of transcript  . Linear functions have proven to be the most versatile in the 
analysis of experimental data sets [22, 43]. In part, this is due to the simplifying power of linear 
functions; they dramatically reduce the number of parameters needed to describe the inﬂuence 
function and avoid problems with overﬁtting. Thus, the amount of data required to solve a linear model 
is much less than that required by more complex nonlinear models a crucial advantage since the high 
cost of experimental data and the high dimensionality of the systems. On the other hand, linear 
functions do not show a rich variety of dynamic behaviour. They only have one isolated stationary state 
in which the temporal change of transcript vanishes, once reaching this state the concentrations of the 
net-work components remain constant. Furthermore, a linear model places strong constraint on the 
nature of regulatory interactions in the cell. Therefore, oscillations or multistationarity, which are both 
important properties of true biological networks, and are nonlinear phenomena, cannot be captured 
with linear models. Also, higher noise in the microarray data limits their application to make only 
qualitative statement and not quantitative statement about the underlying network.  
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ODE-based approaches can be applied to both steady state and time-series expression proﬁles. 
Advantage of ODE approaches is that once the parameters,    for all   are known, Equations 2.12 and 
2.13 can be used to make predictions on the behavior of the network to diﬀerent conditions (i.e. gene 
knock-out, treatment with an external agent, etc.) [46]. 
 
 
2.2.4 Examples of reverse-engineering application 
There are many examples of successful application of reverse-engineering methods applied to 
mammalian cells. In this paragraph I decided to show two examples using association networks based on 
MI [37, 38]. In the 2005 Basso et al. [37] described the application of ARACNe (Algorithm for the 
Reconstruction of Accurate Cellular Networks) on 7907 genes in Human B cells. In ARACNe the MI 
between each pair of genes was estimated using a kernel density approach. The algorithm builds an 
initial graph by connecting all the transcript pairs with a mutual information value associated to a p-
value higher than a chosen significance threshold computed using Monte Carlo simulation. Final pruning 
of the network is achieved by application of the Data Processing Inequality (DPI) principle. DPI asserts 
that if both       and       are directly interacting while       is indirectly interacting through  , then 
                and                . Using this method they were able to reconstruct the 
entire regulatory network of human B cells. The topology of this network suggested a hierarchical and 
scale-free network, with few highly interconnected genes (hubs) accounting for most of the 
connections. They found that MYC was one of the major hubs in this network and they experimentally 
verified some of the new inferred targets, showing that this approach can be generally useful for the 
analysis of normal and pathologic networks in mammalian cells. 
In a more recent work, Belcastro et al. [38] collected a massive and heterogeneous dataset of 
20,255 GEPs from ArrayExpress containing a large variety of human samples and experimental 
conditions. They also collected 8,895 GEPs from mouse samples. In this work, they developed a novel 
mutual information reverse-engineering approach [47]. Using this novel method that takes into account 
this large amount of data, they were able to reconstruct a gene network for human and mouse 
organisms. The inferred connections were compared against known interactions to assess their 
biological significance and successfully experimentally validated a subset of not previously described 
protein–protein interactions. They also showed the existence of co-expressed modules within the 
networks, consisting of genes strongly connected to each other, which carry out specific biological 
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functions, and tend to be in physical proximity at the chromatin level in the nucleus. Finally they showed 
that the network can be used to predict the biological function and subcellular localization of a protein, 
and to elucidate the function of a disease gene. As a case of study they experimentally verified that 
granulin precursor (GRN) gene, whose mutations cause frontotemporal lobar degeneration, is involved 
in lysosome function. 
These two studies represent only a small example of the utility reverse-engineering methods 
and many other works in literature demonstrate that this approach can successfully be used in biology 
to elucidate the complexity of regulatory networks existing in a cell. 
 
 
2.3 Differential networks: methods and applications 
State-of-the-art reverse-engineering methods model gene networks as static processes, i.e. regulatory 
interactions among genes in the network (such as direct physical interactions or indirect functional 
interactions) do not change across different conditions or tissue types. However, different cell-types, or 
the same cell-type but in different conditions, may carry out very different functions, and it is expected 
that their regulatory networks reflect these differences. Several methods have been proposed to 
identify active sub-networks across different conditions from changes in gene expression. Looking genes 
at their functional level comparing the topological structure of gene regulatory networks across 
different conditions provides a more informative level to study genes alteration and their role. 
One of the first attempts was a general method to search for “active sub-networks” connecting 
genes with unexpectedly high levels of Differential Expression (DE) [48]. This method requires in input a 
single network and it identifies a set of genes (i.e. sub-network) whose expression changes across two 
conditions. However, changes in expression may be very mild or absent, even when the sub-network is 
active. Hence, looking only at the differential expression levels of genes could be not sufficient. 
Therefore, more recent approaches attempted to identify Differential Co-regulation (DC) of 
genes in the sub-network [49-57]. By differentially co-regulated genes we mean set of genes which are 
co-expressed only in a specific condition but not in others [58, 59]. Some of these methods works gene-
to-gene and try to identify single genes that exhibit a differential co-expressed pattern across 
conditions. Many studies have shown that observing the strongly altered genes in connectivity could be 
sufficient to identify genes that play an important role in a disease phenotype [49-51]. 
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Some of the most advanced methods instead, go beyond pair-wise co-regulation, and aim at 
automatically identifying denovo sub-network(s) containing genes whose co-regulation changes the 
most across two or more conditions [55-57]. For example Watson et al. [53] proposed a method called 
CoXpress in which clusters across two gene regulatory networks that have significant average 
correlation in the first condition and not in the other are considered differentially co-expressed. This 
approach has been recently extended by Choi et al. [54] using a new pair-wise measure alble to take into 
account also change in the sign of the correlation. 
Other proposed method are more complex and use advanced optimization techniques such as 
genetic algorithms, which, however, are computationally intensive [52], since they require checking all 
of the possible sub-networks to identify the ones that are most dysregulated. Hence, these methods are 
limited in the number of different conditions that can be compared [53-55] and they may require fine-
tuning of the algorithm parameters [57]. 
Recently Langfelder et al. [55] have published a very interesting work to study the network 
module preservation across multiple tissues or conditions. In this work the authors are able to measure 
the conservation of network modules across a set of condition-specific networks. Their method combine 
a permutation test and topological score that aggregate different indexes comprehending also the 
connectivity (or degree) of the genes. 
Other studies have shown how is possible to find who are the genes that have the major 
contribution in the change of topology between two networks. In this area, recently, Odibat et al. [56] 
developed an algorithm able to optimizes an interactive objective function that is a linear combination 
of differential connectivity and differential betweenness centrality. 
The main differences among all of these approaches are in how the genes to be tested are 
selected, how co-regulation is measured (i.e. Pearson Correlation Coefficient or Mutual Information), 
and how differential co-regulation across the conditions is quantified. 
 
2.4 Reverse-engineering post-transcriptional regulatory interactions 
Post-translational modification is a chemical mechanism in which amino-acid residues in a protein are 
covalently modified “on the fly” (Chapter 1). Through this mechanism, a cell is able to tightly regulate its 
activity regulating the localization and interaction of many molecules. Despite the number of human 
kinases that have already been identified, our understanding of phosphorylation-dependent signalling 
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networks is still very fragmentary. Considering that only about 500 human protein kinases are the actors 
of all the known signaling networks, only for a third of phosphorylation-sites identified so far, the 
kinases/phosphates is known. [60] 
Due to the importance of the post-translational events, many researches were motivated to 
map phosphorylation networks.  This has lead to the development of new computational methods to 
predict the substrate specificities of protein kinases. Some of these methods use a “sequence” 
approach. They are essentially based on experimental identification of the consensus sequence motifs 
recognized by the active site of kinase catalytic domains [61-63]. However, these motifs often lack 
sufficient information to uniquely identify the physiological substrates of specific kinases. 
Other methods instead take into account also other kind of data [64-66] including gene 
expression and gene co-regulation. Here, in particular I will briefly discuss two of these methods. One 
has been recently proposes by Linding et al. [64], who developed a novel integrative computational 
approach, called NetworKIN. This method is designed to link experimentally identified phosphorylation 
sites to protein kinases. To predict protein kinases substrate, NetworKIN method combines consensus 
information from motifs with protein association networks. Basically, the method consists of two steps. 
In the first step, it uses neural networks and position-specific scoring matrices to assign each 
phosphorylation site to one or more kinase families, based on the intrinsic preference of kinases for 
consensus substrate motifs. In the second step, the context for each substrate is restricted using a 
probabilistic framework extracted from the STRING database [67], which integrates information from 
different kind of sources including: curated pathway databases, co-occurrence in abstracts, physical 
protein interaction assays, mRNA expression studies, and genomic context. They successfully applied 
their method to DNA damage signaling, showing that 53BP1 and Rad50 are phosphorylated by CDK1 and 
ATM, respectively. 
In another recent work, Califano et al. [65] proposed a scheme where the ability of a 
transcription factor    to regulate a target gene   is modulated by a third gene   (the modulator). 
Pairwise analysis of mRNA expression profiles will generally fail to reveal this complex picture because 
  and    (e.g., a kinase and a transcription factor it activates/deactives) are generally statistically 
independent, and because the correlation between the expression of    and   is averaged over an 
entire range of values of  and thus significantly reduced. The authors proposed a novel method called 
MINDy (Modulator Inference by Network Dynamics) that use conditional Mutual Information 
      |   from gene expression profiles to detect such regulation, by conditioning on the expression 
level of the modulator. Hence, MINDy is a gene expression profile method based on a pair-wise 
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information-theoretic measure known as the conditional mutual information, for the identification of 
genes that modulate the transcriptional program of a transcription factor at the post-translational level. 
Since accurate estimation of the conditional mutual information requires large datasets MINDy needs a 
large gene expression profile dataset to work. The authors used MINDy to dissect the post-translational 
regulation of MYC activity in human B lymphocytes. Using this approach they were able to infer novel 
post-translational modulators of MYC [65] showing that also with gene expression it is possible infer 
post-transcriptional regulation. 
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Chapter 3 
Reverse Engineering Tissue-Specific Transcriptional Networks 
Due to the large diffusion of microarray technologies in the last decade, public repositories have been 
released to store and annotate these data for the scientific community. A standard called MIAME has 
also been proposed [25] to consistently annotate these gene expression data from microarray. In this 
chapter, I will present a software pipeline able to retrieve and classify in a semi-automatic way 
microarray experiments containing feature of interest. Using this pipeline, I was able to collect 2390 
microarray experiments divided in 30 tissues. Finally the reverse-engineering technique used for the 
identification of the 30 tissue specific networks and their validation will be presented. Part of this 
Chapter has been published in the work of Gambardella et al.  “Differential Network Analysis for the 
identification of condition-specific pathway activity and regulation” in press in the journal Bioinformatics 
[68]. 
 
3.1 Construction of a semantic database for tissue-specific gene 
expression profiles 
One of the main problems in using Gene Expression Profiles (GEPs) from public repositories is the poor 
state of the experiments meta-data containing information on the biological samples and experimental 
protocols. In order to select tissue-specific GEPs, I built a semi-automatic tool to download and classify 
the MAGE-ML [25] annotation files present in the ArrayExpres [24]. This tool includes a semantic 
database [68] which structure is built round  the eVoc human tissue ontology [69]. The database allows 
storage and retrieval of the classified experiments. I was thus able to assign to each GEP the correct 
tissue, according to the available meta-data, and selected only GEPs with a reliable annotation. I was 
thus able to collect 2930 high-quality GEPs (Affymetrix HG-U113A and HG-U133 Plus 2.0 platforms) for 
30 different tissues (Table 1). 
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Table 1 – The Number of gene expression profiles collected for each tissue, using the semi-automatic tool to retrieve and 
classify Geps presents on ArrayExpress. 
Tissues # of Geps 
ADIPOSE TISSUE 49 
ADRENAL GLAND 88 
BLOOD 268 
BONE MARROW 180 
BRAIN STEM 62 
BRONCHUS 79 
CARTILAGE 60 
CEREBELLUM 49 
CEREBRUM 109 
COLON 66 
DUODENUM 61 
HEART 124 
INTESTINE 108 
KIDNEY 206 
LIVER 86 
LUNG 108 
LYMPH NODE 43 
MAMMARY GLAND 264 
MIDBRAIN 55 
MUCOSA 61 
OVARY 56 
PANCREAS 51 
PLACENTA 47 
PROSTATE 102 
SKELETAL MUSCLE 94 
SKIN 76 
TESTIS 61 
THYROID 43 
UMBELLICAN CORD 84 
UTERUS 190 
 
 
 
The main feature of this database is its “semantic” property, consisting in the fact that it integrates a 
tissue-based ontology, which can be used to classify and retrieve all the hybridizations regarding a tissue 
of interest. Formally, to retrieve all the hybridization of a tissue means to retrieve all the hybridizations 
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that have an IS-A relationship with the tissue of interest. In a Relational Database Management System 
(RDBMS) to manage in an efficient way this kind of recursive query, ad-hoc structure are necessary. 
Here, I decided to use, and thus to implement, the solution proposed by Kimball et al. in [70] 
where they employed a bridge table to model a 1 to N association with the table containing the 
ontology terms. This strategy allows flattening the hierarchies present in the ontology. 
 
 
 
 
Figure 8 –Example of bridge table necessary to store the tree shown on the in left. The bridge table contains one row for each 
pathway in the tree, as well as a row for the zero-length pathway from a node to itself. Each row of the bridge table contains 
the node key of the parent and of its descendant, the number of levels between the parent and the descendant and finally, a 
flag to indicate that there are no further nodes above the parent, which indicates if this descendant is a leaf or not. 
 
 
As shown in Figure 8 the bridge table contains one row for each pathway in the tree, from a node (i.e. 
ontology term) to every other node in the tree, as well as a row for the zero-length pathway from a 
node to itself. Each row of the bridge table contains the node key of the parent and of its descendant, 
the number of levels between the parent and the descendant and finally, a flag to indicate that there 
are no further nodes above the parent, which indicates if this descendant is a leaf or not. 
Obviously the dimension of the bridge table grows exponentially with the depth of the three, 
but here, the ontology I used has maximum depth equal to 6 and thus only 1200 rows are necessary to 
store it, which is an easily manageable number by any RDBMS. 
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3.2 Spearman Correlation Coefficient 
The Spearman Correlation Coefficient (SCC) is a nonparametric measure of statistical dependence 
between two variables. It measures the strength of a monotonic relationship between paired data. 
Usually, SCC is denoted by the Greek letter   or   . The Spearman correlation coefficient is defined in 
the same way as the Pearson Correlation Coefficient (PCC) but it uses the ranks of the variables rather 
than their values. Given two variables   and   of size  , we first have to convert the   raw scores   ,     
into the ranks,       and then we can compute    as: 
 
   
∑      ̅      ̅  
√∑      ̅   ∑      ̅   
 
 
If there are identical values (i.e. rank ties or value duplicates), we assign a rank equal to the average of 
their positions in the ascending order of the values. In the case of absence of identical values    can be 
easly computed as: 
 
   
 ∑   
 
 
       
 
 
where the difference          is the difference between the ranks of the observations for the two 
variables. 
The sign of the Spearman correlation indicates the direction of association between the variable 
  and the variable  . The SSC will be positive if and only if   tends to increase when   increases, 
otherwise if   tends to decrease when   increases the SSC will be negative. A SCC equal to zero means 
that there is no tendency for   to either increase or decrease when   increases. The SCC becomes equal 
to 1 when   and   are perfectly monotonically related. By definition a perfect monotone relationship 
between two variable   and   implies that for any two pairs of data values   ,    and   ,   , the 
differences       and       always have the same sign for each   and  . In particular if the sign is 
positive we are talking about an increasing monotone relationship and of an decreasing monotone 
relationship if the sign is negative. 
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Figure 9 - Spearman correlation coefficient (SCC) between two variables is equal to 1 when they are monotonically related, 
even if their relationship is not linear, unlike the Person correlation coefficient (PCC). 
 
 
The calculation of SCC and its significance test, unlike the Person Correlation Coefficient (PCC), do not 
require the normality distribution assumption of the data, but only the ordinal assumption. For this 
reason SCC is considered a nonparametric statistic. 
The significance of SCC can be tested using the following formula [71] 
 
   √
   
    
 
 
which is distributed approximately as Student's t distribution with       degrees of freedom under the 
null hypothesis. 
 
 
45 
 
3.3 Reverse engineering of tissue-specific gene co-regulation networks 
Using the database described in Section 3.1, I was able to classify 2930 microarrays (Affymetrix HG-
U133A and HG-U133plus2) extracted from ArrayExpress in 30 different tissues [68]. To avoid batch 
effect, I decided to normalize microarrays  independently for each tissue. The normalization algorithm 
used was RMA (Robust Multichip Average) as implemented in the R package Bioconductor [72]. Then I 
computed the Spearman Correlation Coefficient, as described in Section 3.2, for each pair of probes in 
each tissue, obtaining (excluding control probes) a final correlation matrix of dimension 22,215 x 22,215 
for each tissue.  The SCC significance for each pair of probes was computed fitting a Students’ t 
distribution on the t-statistics obtained from all the SCC value.  
Formally, in order to control the number of False Positives due to the multiple hypotheses test 
problem, I estimated the degrees of freedom of the t distribution from the data by fitting the 
parameters of a Student's t-location-scale distribution to the t statistics computed for all the probe 
pairs. I estimated the parameters by minimizing the squared error between the theoretical and the 
empirical distribution. In particular a Student's t-location-scale distribution of degree  , mean   and 
standard deviation   has the density function as follow: 
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with location parameter  , scale parameter   and shape parameter     and if   has a t-location-scale 
distribution with parameters  ,   and  , by definition 
   
 
 has a Student's t distribution with   degrees 
of freedom. 
Finally, to obtain the gene-wise SCC matrices, I used the following strategy: starting from the 
probe-wise SCC matrices, I first excluded probes that were associated to more than one gene using the 
tool proposed here [73], but still keeping genes associated to more than one probe. Specifically, using 
this tool to annotate probes of Affymetrix platforms [73], I was able to map 12161 genes from the 
probes in the HG-U133A platform. Out of these 12161 genes, 68% of the genes were associated to only 
one probe (Figure 10A) and only 11% of genes were associated to more than 2 probes (Figure 10B). 
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Figure 10 – Relationship between probes and genes on the HG-133A Affymentrix platform (a) Distribution of the number of 
probes associated to genes on the HG-U133A Affymetrix platform. x-axis: number of probes; y-axis: the pergentage of genes. 
(b) cumulative distribution of the genes versus associated number of probes. x-axis: the number of probes associated; y-axes: 
the pergentage of genes.  
 
 
Hence, for the same pair of genes, there could be multiple values of the SCC, because the same gene 
might be associated to multiple probes in the microarray. In this case, I decided to assign to the gene 
pair, the “signed” maximal absolute value of SCC across all the different probe-pairs, deriving at the end 
of this procedure 30 gene-wise networks from the 30 probe-wise networks. 
An alternative way to transform the probe-wise SCC matrices to gene-wise SCC matrices would 
have been to apply a “gene centered” normalization [74] of the microarrays using a custom CDF, prior to 
the SCC computation, thus eliminating the problem of multiple SCC values. We however decided to 
preserve information on possible alternative transcripts for future work and for experimental validation.  
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Finally, although Mutual Information (MI) has been shown to be a better alternative to 
correlation in identifying co-regulated genes [37, 38], because of  the limited number of GEPs available 
for some tissues, I decided to use the Spearman Correlation Coefficient (SCC). I also decided not to use 
any network pruning techniques [35, 37] since I am not interested in distinguishing between direct and 
indirect interactions, but rather in how the co-regulation network among genes changes across the 
different tissues. 
 
 
 
3.4 Validation and analysis of transcriptional networks 
To verify the biological relevance of the tissue-specific gene networks, I computed the PPV-Sensitivity 
curve for each of the 30 co-regulation networks using as a “Golden Standard” the Ractome database 
[75]. Reactome is a database composed by manually curated interactions of genes and proteins 
participating to the same pathways.  
For each network, I computed the percentage of co-regulated genes for which a regulatory 
interaction was confirmed by the Golden standard (                                   ⁄ ). As 
shown in Figure 11, all of the 30 tissue specific co-regulatory networks have a Positive Predicted Value 
(PPV) significantly higher than what would be expected by chance [68]. 
Moreover, since each network was constructed using a different number of GEPs, I also verified 
that the different performance in PPV across the networks was not related to the number of GEPs used 
for the construction of each network. As shown in Figure 12 there is no correlation between the number 
of experiments used to build the network and its performance in PPV. PPV performance is measured in 
this case as Area Under the Curve (AUC) up to 1% of sensitivity. 
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Figure 11 – Biological relevance of the 30 tissue specific co-regulation networks. I used as a Golden Standard, an interactome 
consisting of about 25,000 experimentally verified biological interactions from the Reactome database. The Positive Predictive 
Value (             ⁄  ) vs. Sensitivity (         ⁄ ) curve for each of the 30 co-regulation networks is reported. 
The random performance is also shown for comparison (PPV Random = 0.014). (Figure taken from [68]) 
 
Figure 12 - Relationship between Area Under the Curve (AUC) and the number of GEPs in each tissue. Differences in 
performance (AUC) across the different networks is not due differences in the number of GEPs in each tissue. x-axis: AUC (up to 
a sensitivity of 1%) for each of the 30 networks. y-axis: number of GEPs in each tissue used to infer the network. The PCC 
(Pearson Correlation Coefficient) is 0.0977 with a p-value of 0.6075. (Figure taken from [68]) 
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As a further proof of the biological relevance of the tissue specific-regulatory networks, I corroborated 
some recent results observed by analyzing tissue-specific Protein-Protein Interaction (PPI) networks by 
Lehner et al [76, 77]. In this work, the authors investigated human tissue-specific protein-protein 
interactions across 79 tissues, by assigning to each protein a tissue-specificity, if the corresponding 
coding genes was expressed in that tissue. They were able to show that tissue specific proteins 
(identified as the ones whose genes are expressed in one or few tissues) make few protein interactions, 
as compared to universally expressed proteins, and they tend to appear more recently during evolution. 
Here, using a completely different approach based on tissue specific co-regulation networks 
inferred from tissue specific GEPs, I was able to draw similar conclusions: i.e. genes with tissue specific 
expression tend to be co-regulated with a smaller number of genes, as compared to ubiquitously 
expressed house-keeping genes (Figure 13A) and that evolutionary conservation is related with tissue-
specific regulation (Figure 13B-C). In particular, in order to identify the specificity of a gene in a tissue, I 
used a set of GEPs measured across 79 human tissues [78] (i.e. the same set of GEPs used by Lehner). 
Specifically, in this dataset a gene is considered expressed in a tissue, if its normalized expression level is 
     [78]. 
Finally, as a further proof of the biological relevance of the tissue-specific co-regulation 
networks, we identified which connections were conserved across the majority of the 30 networks. As 
shown in Figure 14, 3235 co-regulatory connections involving 993 distinct genes are conserved in at 
least half of the tissue-specific networks. In particular, these connections are enriched for 
“housekeeping” cellular functions such as ribosomal and cell cycle functions. 
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Figure 13 - Tissue specific genes and gene conservation as function of connection degree across the 30 co-expression networks. 
(a) Average connection degree of a gene across the 30 co-regulation networks as a function of the number of tissues in which it 
is expressed. x-axis: number of tissues in which a gene is expressed computed from the GENE ATLAS dataset [78]. y-axis: the 
average gene interaction degree across the 30 tissue specific co-regulation networks. The dashed line represents the linear 
regression with the corresponding p-value 0.037. (b) The phylogenetic tree, the pentagon marks the common ancestor of the 
15 species (highlighted) used in the analysis. Numbers on each branch are the phylogenetic distances computed by Ciccarelli et 
al in [79]. (c) x-axis: phylogenetic distance of a gene computed as the distance between the root of the tree (pentagon in a) and 
the common ancestor of the species in which the gene is conserved. That is, the value 0 identifies genes conserved in all the 15 
species, while the value 0.4096 identifies genes present only in human. y-axis: average gene interaction degree across the 30 
co-regulation networks. The dashed line was obtained by linear regression shows the tendency of old genes to be more co-
regulated compared with young genes (P-value = 0.0085). 
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Figure 14 - Conserved connections across the majority of the 30 tissue specific co-regulatory networks. The graph represents 
the 3235 co-regulatory connections, involving 993 distinct genes, which are conserved in at least the half of the tissue specific 
co-regulation networks and their Gene Ontology Enrichment. (Figure taken from [68]) 
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Chapter 4 
A new approach to Differential Network Analysis 
 
Identification of differential expressed genes has led to countless new discoveries. However, 
differentially expressed genes are only a proxy for finding condition-specific or dysregulated pathways. 
In this chapter, we will address the problem in which we want to identify how networks of regulatory 
and physical interactions rewire in different tissues or in during disease progression.  I will first present a 
new method that I developed. I called this method DINA (DIfferential Network Analysis). This new 
procedure, starting from a collection of condition-specific gene expression profiles and a set of genes 
used as a query (i.e. a pathway), it is able to identify whether genes in the query set are co-regulated in 
a condition-specific manner.  In this chapter, I will be also present an extension of DINA to predict which 
transcription factors may be responsible for the pathway condition-specific co-regulation. Part of the 
work here described is in press in the journal Bioinformatics [68]. 
 
4.1 A new approach to DIfferential Network Analysis (DINA) 
The working hypothesis behind this new method I developed is that genes belonging to a condition-
specific pathway are actively co-regulated only when the pathway is active, independently of their 
absolute level of expression. To this end, I developed a network-based algorithm, DINA (DIfferential 
Network Analysis), which is able to identify whether a set of genes (e.g. a pathway) is significantly co-
regulated only in specific conditions, but not in others, as schematically described in Figure 15A.  
The input to DINA is a set of  genes (i.e. genes belonging to a known pathway) and a set of   
condition specific networks. DINA used the input and the networks to compute a “co-regulation 
probability” for the input   genes in each of the   networks; this probability is simply proportional to 
the number of edges among the genes in each network.  
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Figure 15 - Differential Network Analysis. (a) Graphical description of the DIfferential Network Analysis (DINA) method to 
quantify the variability of co-regulation among the genes in a pathway across multiple networks. (b) Graphical description of 
the method used to identify the transcriptional regulators of the genes in a pathway across multiple networks. (Figure taken 
from [68]) 
 
 
DINA [68] then quantifies how variable the co-regulation probability is across a set of   condition 
specific networks. The variability is quantified using an entropy-based measure ( ) and its significance is 
estimated using a permutation test that I will describe in details in the following section. 
In information theory, entropy is a measure of the uncertainty associated to a random variable. 
If   is a discrete random variable assuming   categorical values, its entropy      can be estimated as 
follows: 
 
     ∑         
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From the property of entropy,   reaches its maximum value when each event is equi-probable and its 
minimum, i.e.      , when there is no uncertainty. 
Specifically, in our settings,   assumes   categorical values, representing the   condition-
specific networks. In order to compute        I first computed the number of edges    connecting the 
  genes in the     network (adding a pseudo-count of 1) with   {     }, and I then computed 
       
  
∑   
 
   
. 
       can be interpreted as a probability, because it is a number greater than 0 and it sums 
to 1 across all the N condition-specific networks by definition. Specifically,        will be equal to 1 if 
and only if the genes in the pathway are specifically co-regulated (i.e. connected) in network   and not 
co-regulated (connected) in any other network. In this case, H(V) will be equal to zero, indicating  that 
the M genes are condition-specific. Thus        represents the probability that  genes in a pathway 
are co-regulated only in the     network and not in the other networks, and the value of     quantifies 
how condition specific the  genes are. 
In order to assess the entropy significance (i.e. the condition specificity of a pathway) I used 
permutation test. The null distribution of      is approximated by selecting a set of   random 
networks, with the same density as the original networks, and a set of   random genes. Random 
networks are obtained from the original network by randomly shuffling the gene labels. This procedure 
is repeated 10,000 times in order to estimate the      p-value for the M genes in the query set. The p-
value is estimated by counting how many times the      value computed on the query set is greater 
than the H(V) value computed on the random network. The p-value can then be corrected using the 
Benjamini-Hochberg method if multiple query set are given in input to DINA [80]. 
Summarizing, the key concept of the proposed method is this: if the   genes of interest have 
the same co-regulation probability across the   networks, then the entropy   will be high; on the other 
hand, if the   genes have a high co-regulation probability only in one (or few) networks (i.e. the 
pathway activity is condition-specific), than the entropy   will be low (hence we are interested in 
pathways associated to a low ). 
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4.2 Identification of transcriptional regulators of tissue-specific 
pathways 
I then developed also a simple method for the identification of Transcription Factors regulating a 
condition-specific pathway [68] identified by DINA. The input to this algorithm is a pathway of interest 
(i.e. a set of M genes) and the output is a ranked list of Transcription Factors according to a p-value, 
estimated as described below. The algorithm iteratively tests all the transcription factors by computing 
for each one the number of edges connecting it to the genes in the pathway of interest in each of the 
condition specific networks, as depicted in Figure 15B. The method assigns a p-value to each tested TF 
using the non-parametric Fisher's exact test, by comparing, in each tissue, the number of edges between 
the TF and the genes in the pathway to the number of all the possible edges between the TF and the 
genes minus the real number of edges. The p-value was then corrected using the Benjamini-Hochberg 
method [80]. 
 
 
4.3 A case of study: Identification of tissue-specific pathways  
To test whether DINA was able to identify tissue-specific pathways, i.e. pathways which are actively 
regulated only in specific tissues, I used the full manually curated list of 186 KEGG pathways from 
MsigDb [81, 82]. This list includes many different types of pathways including signaling, metabolic and 
regulatory pathways. By definition a pathway in KEGG is a set of genes known to work as a functional 
module in a regulatory network. From this list, I removed from the set of 186 KEGG pathways those 
pathways not well represented in our gene networks, described in Chapter 3, i.e. those pathways for 
which at least 80% of the genes had to be present obtaining a final list of 110 KEGG pathways to test. 
By applying DINA to the tissue-specific networks and the list of 110 KEGG pathways, I obtained 
22 significant tissue specific pathways (with corrected p-value<0.01) [68]. One of these is for example 
the Glycine, Serine and Threonine metabolic pathway (KEGG hsa00260). This pathway was correctly 
identified by DINA to be mainly regulated in liver and kidney, where most of the glycine to serine 
metabolism occurs [83]. Interestingly, among the 22 significant pathways, 9 are indeed metabolic 
pathways enriched in liver and kidney (Table 2 pathways in red). 
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Table 2 – The list of 22 significant tissue specific pathways identified by DINA with a p-value threshold of 0.01. Coloumn H 
contains the entropy value coputed by DINA. 
KEGG PATHWAY H P-val(corrected) 
KEGG_COMPLEMENT_AND_COAGULATION_CASCADES 3.72 0 
KEGG_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION 3.85 0 
KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION 3.90 0 
KEGG_DNA_REPLICATION 3.91 0 
KEGG_CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 4.09 0 
KEGG_HEMATOPOIETIC_CELL_LINEAGE 4.24 0 
KEGG_CALCIUM_SIGNALING_PATHWAY 4.25 0 
KEGG_CELL_ADHESION_MOLECULES_CAMS 4.39 0 
KEGG_JAK_STAT_SIGNALING_PATHWAY 4.41 0 
KEGG_CHEMOKINE_SIGNALING_PATHWAY 4.46 0 
KEGG_PROPANOATE_METABOLISM 4.11 0.00095 
KEGG_GLYCINE_SERINE_AND_THREONINE_METABOLISM 4.12 0.00095 
KEGG_BUTANOATE_METABOLISM 4.14 0.001477 
KEGG_PEROXISOME 4.31 0.001477 
KEGG_MISMATCH_REPAIR 4.15 0.001995 
KEGG_ARGININE_AND_PROLINE_METABOLISM 4.18 0.001995 
KEGG_FATTY_ACID_METABOLISM 4.16 0.002891 
KEGG_LYSINE_DEGRADATION 4.23 0.002891 
KEGG_PURINE_METABOLISM 4.53 0.002891 
KEGG_OTHER_GLYCAN_DEGRADATION 4.41 0.00665 
KEGG_FOCAL_ADHESION 4.60 0.006916 
KEGG_TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY 4.47 0.008184 
 
 
 
Figure 16A shows the co-regulation probability of the 32 genes in the Glycine, Serine and Threonine 
metabolic pathway in each of the thirty tissues, as previously defined and for comparison, Figure 16B 
shows the average expression level of the genes in the pathway in each of the 30 tissues. Notable is that 
expression levels do not change significantly across the tissues, whereas the co-regulation probabilities 
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(Figure 16A) are strikingly different, showing that to look only at the expression level,  could be not 
sufficient to obtain the right answer.  
To underline the fail of an approach only based on gene expression, we also checked in the 
Gene Atlas Dataset for the expression level of the genes encoding for the enzymes involved in this 
pathway [78], Using the canonical expression level threshold of 200 [78], we found that only 13 out of 
32 genes are expressed in liver, and only 2 out of 32 are expressed in Kidney (Figure 17). 
As shown in Figure 18 and Figure 19, similar considerations can be applied to the other 
significant metabolic pathways identified by DINA (Table 2 pathways in red). Hence, an approach based 
on expression levels (and not co-regulation) would not have been able to identify these tissue-specific 
metabolic pathways. 
 
Figure 16 - Differential Network Analysis of the Glycine pathway (KEGG hsa00260). (a) Co-regulation probability of the 32 genes 
in the Glycine path-way (hsa00260) across the thirty tissues. (b) Average expression level of the 32 genes in the Glycine 
pathway (hsa00260) across the thirty tissues (error bars represent one standard deviation). (Figure taken from [68]) 
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Figure 17 - The number of expressed genes that encode for the enzymes in the glycine pathway (KEGG hsa00260) across the 79 
tissues of gene atlas dataset. Out of 32 genes only 13 are expressed in liver, 4 in fetal liver and only 2 in Kidney. (Figure taken 
from [68]) 
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Figure 18 –Co-regulation probability among the genes that encode for the enzymes in the 9 significant metabolic pathways 
identified by DINA reported in Table 2. (Figure taken from [68]) 
 
 
 
 
Figure 19 - Average expression among the genes that encode for the 9 significant metabolic pathways identified by DINA 
reported in Table 2. (Figure taken from [68]) 
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4.4 A case of study: Identification of disease-specific pathways 
dysregulation 
Gene expression alteration is a common molecular hallmark of cancer progression. In the last decade, 
the identification of cancer genetic signatures has been successfully exploited for understanding the 
mechanisms of cancer development [84], as well as, for anticancer therapies selection [85] and diseases 
prognosis [86]. Moreover, recently, with the help of reverse-engineering approaches also some specific 
cancer-regulated gene regulatory networks have been identified [87, 88]. Here, I wondered whether 
DINA could be successfully employed to identify selective alterations of co-regulated gene networks in 
cancer. Since several cell-lines modelling HCC progression are available, as well as, GEPs measured in 
these cell lines, as a study model, I focused my attention on Hepatocellular Carcinoma (HCC). 
It is well established that HCC progression involves alterations in many fundamental signalling 
pathways, such as EGF-Ras-MAPK, AKT-mTOR, Jak-Stat, and NF-kB cascades [89]. In addition, inactivating 
mutations of the tumor suppressor p53, or p53 loss of expression, are among the most frequent genetic 
events associated with hepatocyte transformation [90, 91] and the dysregulation of p53-dependent 
genes have been observed in HCC [92, 93]. 
Here, in order to mimic the progression of HCC, I reverse engineering cell-type specific gene 
networks using the Spearman Correlation Coefficient by collecting a total of 161 GEPs for three human 
cell-lines: primary hepatocytes (40 GEPs), hepatoblastoma-derived cell line HepG2 (39 GEPs) and 
Hepatocarcinona-derived cell line (Huh7) (82 GEPs). From these GEPs I first reverse-engineered the 
three co-regulation networks for each one of the different cell-lines. Then, I tested the ability of DINA to 
identify differential co-regulation of p53-dependent genes across these three condition specific gene 
regulatory networks, since the Huh7 cell-line has an inactivating mutation for p53 [91].  
To this purpose, I built a gene signature made up by 34 transcriptional targets of p53 [94] and I 
then applied DINA to this gene signature, as shown in Figure 20. 
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Figure 20 - Differential Network Analysis of the p53 gene signature in primary and transformed hepatocytes. The gene signature 
consists of 34 experimentally verified transcriptional targets of p53. (a) p53 expression level in the three cell-lines for the two 
probes present in Affy HG-U133A platform. (b) Comparison between the co-regulation probability of the genes in the signature 
(black) and their average expression level. (Figure taken from [68])  
 
 
As shown in Figure 20, DINA successfully detected a differential co-regulation of the p53 target genes 
across the three cell lines: the co-regulation probability is high in normal hepatocytes and, to a lesser 
extent, in hepatocellular carcinoma HEPG2 cell line, carrying a wild type p53 protein, and decreases 
significantly in Huh7 cell line, carrying an inactive p53 protein [91] (Figure 20B).  Interestingly, the 
expression level of the p53-target genes did not correlate with the functional status of the p53 protein 
in the different cell lines, thus supporting my previous observation (Figure 20A) that an expression-
based method would be less powerful than the DINA in identifying dysregulated pathways. 
I next applied DINA to identify dysregulated pathways during hepatocytes transformation. The 
DINA-based analysis of the 110 KEGG pathways identified at least five pathways whose co-regulation is 
significantly disrupted in the hepatocarcinoma cell lines compared to the normal hepatocytes (Table 3).  
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Similarly to the previous results, the average expression levels of the genes in these pathways did not 
change significantly between normal and transformed hepatocytes (Table 3). 
 
 
Table 3 – List of pathways that DINA get dysregulated. The entropy value (H) are reported with their p-values (corrected and 
not). Red bold pathways are significantly disrupted pathway found by DINA. As a comparison also the average expression of the 
pathways is reported for each cell line. 
PATHWAYS H P-val 
P-val 
(Corected) 
Avg. exp. 
primary 
hep. 
Avg. exp. 
hepg2. 
Avg. exp. 
huh7. 
KEGG_PRIMARY_BILE_ACID_BIOSYNTHESIS 0.5490 0.0000 0.0000 7.36 6.50 6.37 
KEGG_PEROXISOME 0.5912 0.0004 0.0220 8.21 7.60 7.48 
KEGG_PHENYLALANINE_METABOLISM 0.7229 0.0009 0.0330 8.54 7.62 7.26 
KEGG_GLYOXYLATE_AND_DICARBOXYLATE_METABOLISM 0.8031 0.0014 0.0385 8.58 8.20 8.16 
KEGG_TYROSINE_METABOLISM 0.6211 0.0019 0.0418 7.57 7.03 6.59 
KEGG_COMPLEMENT_AND_COAGULATION_CASCADES 0.8866 0.0064 0.1173 8.62 7.60 7.45 
KEGG_VALINE_LEUCINE_AND_ISOLEUCINE_DEGRADATION 0.7811 0.0133 0.2063 8.40 7.84 8.04 
KEGG_PPAR_SIGNALING_PATHWAY 0.9003 0.0150 0.2063 7.60 7.19 7.10 
KEGG_TRYPTOPHAN_METABOLISM 0.8254 0.0172 0.2102 8.47 7.29 7.13 
KEGG_FATTY_ACID_METABOLISM 0.8554 0.0201 0.2211 8.03 7.57 7.47 
KEGG_ALANINE_ASPARTATE_AND_GLUTAMATE_METABOLISM 0.9041 0.0267 0.2325 8.06 7.69 7.47 
KEGG_GLYCINE_SERINE_AND_THREONINE_METABOLISM 0.9193 0.0317 0.2325 8.45 7.54 7.70 
KEGG_LINOLEIC_ACID_METABOLISM 0.9364 0.0300 0.2325 8.07 5.87 5.36 
KEGG_PROPANOATE_METABOLISM 0.9154 0.0305 0.2325 8.30 7.80 7.73 
KEGG_BUTANOATE_METABOLISM 0.8987 0.0277 0.2325 8.04 7.56 7.27 
KEGG_BETA_ALANINE_METABOLISM 0.9997 0.0386 0.2654 7.73 7.15 7.17 
KEGG_PROXIMAL_TUBULE_BICARBONATE_RECLAMATION 1.0211 0.0483 0.3125 7.39 7.38 7.17 
 
 
Interestingly, the most significant loss of co-regulation observed in transformed hepatocytes involves 
the peroxisome metabolism (KEGG ko04146), the primary bile acid biosynthesis (map00120), and the 
glyoxylate and dicarboxylate metabolism (map00630): these pathways are responsible for fundamental 
functions in liver cells such as the synthesis of bile acids, cholesterol, the oxidation of fatty acid, the 
metabolism of phenyalanine, the glyoxylate and the tyrosine metabolism. Moreover, among the other 
dysregulated pathways identified by DINA, we found disruption of fundamental pathways regulating 
liver cancer progression such as the PPAR signaling pathway (Table 3). 
In order to gain further insights into the dysregualtion of the peroxisome metabolism, I analyzed 
the changes in the gene co-regulation network among the corresponding genes across the three cell 
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lines. Figure 21A and Figure 21B demonstrate that there is a major loss of co-regulation among 
peroxisome related genes in both HepG2 and Huh7 hepatocarcinoma cell lines; moreover this loss 
mainly results from dysregulation of genes involved in peroxisomal fatty acid -oxidation (e.g. ACOX, 
EHHADH, ACAA1) and genes involved in the control of the H202 metabolism (e.g. CAT and SOD). 
Notably, these genes are regulated by the peroxisome proliferator-activated receptor alpha (PPARalpha) 
[95] and the LXR family transcription factors [92]. 
Thus, the DINA results indicate that the dysregulation in the activity of these liver specific 
transcription regulators may represent a recurrent event associated with hepatocarcinoma. Consistent 
with these results, peroxisome and PPARalpha pathway alterations have been definitely associated with 
liver cell proliferation and with hepatocarcinoma development [96], confirming the efficacy and 
specificity of DINA algorithm in identifying condition-specific pathway regulation. 
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Figure 21 - Differential Network Analysis of the peroxisome KEGG pathway (M6391) in primary and transformed hepatocytes. 
Genes in the peroxisome pathway are represented as circles; a significant co-regulation between two genes as a line. The size of 
the circles is proportional to the difference in the number of edges between the networks in transformed hepatocytes versus 
primary hepatocytes. Gray lines represent edges lost in the network com-pared to primary cells. (a) HepG2 versus primary 
hepatocyte; (b) HepG2 versus primary hepatocyte. (Figure taken from [68]) 
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4.5 A case of study: YEATS2: a negative transcriptional regulator of 
metabolic pathways 
I wondered whether it was possible to identify transcription factors (TFs) regulating tissue-specific 
pathways identified by DINA [68]. The working hypothesis was that a TF, controlling a tissue-specific 
pathway, may be co-regulated with its target genes only in that tissue but not in others (Figure 15B). 
Since the regulation of metabolic pathways has been well studied in the past, we decided to identify TFs 
involved in the regulation of the 9 metabolic pathways (Table 2 in red) previously identified by DINA. 
To this end, I used the list of 1358 human genes including both genes, whose protein product 
has a verified TF activity [97], as well as, genes encoding proteins with an indirect transcriptional activity, 
such as co-factors or scaffolding proteins. For each of the 9 metabolic pathways previously identified as 
tissue-specific, and for each TF in the list, I applied the method presented in the paragraph 4.2 to select 
TFs sharing a significant number of edges with the genes in the pathway only in the tissue(s) where the 
pathway is active, as shown in Figure 15B. 
Table 4 lists the master TFs controlling the majority (i.e. 7 out of 9) of the metabolic pathways 
according to our analysis. Considering only genes encoding proteins with a known TF activity (Table 4 in 
bold), this method correctly identified many nuclear receptors as specific regulators of these pathways 
(NR1H4, NR1I3, ESRRG, HNF4A). The nuclear receptor super-family is one of the largest groups of TFs 
involved in the regulation of different metabolic processes [98], such as the regulation of liver 
metabolism [99]. 
For example, as shown in Table 4, one of the six nuclear receptors is HNF4A, probably the most 
famous nuclear receptor in liver, whose mutations are responsible for monogenic autosomal dominant 
non-insulin-dependent diabetes mellitus type I (MODY1) [100]. The protein encoded by this gene 
controls the expression of several genes, including hepatocyte nuclear factor 1 alpha (HNF1A), a 
transcription factor that regulates the expression of several hepatic genes. 
When we considered also genes encoding proteins indirectly involved in transcription [97] 
(Table 4 not in bold), we identified, among others, SIRT4 (sirtuin 4), a member of the sirtuins' family that 
plays a key role in human metabolic regulation [101-103]. 
Among the list of protein indirectly involved in the regulation of transcription, the gene YEATS2 
has attracted my attention because was predicted by DINA to be the most significant negative regulator 
shared by most of the metabolic pathways (Table 4  not in bold). I checked for the expression level of 
YEATS2 as described in [104], and I observed that YEATS2 gene is expressed at very low levels in both 
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liver and kidney and, at the time of writing of this thesis, very little is known about its function. Recently, 
it has been demonstrated that YEATS2 interacts with the ATAC complex (Ada-Two-A-Containing) [105], 
which, together with SAGA (Spt-Ada-Gcn5-Acetyl-Transferase), is able to modulate transcription, both 
by causing chromatin modification and by interacting with the TATA-binding proteins (TBPs) [105, 106]. 
But no association of this gene with metabolism is existent until now in literature. 
In order to validate DINA’s prediction about the involvement of YEATS2 in the transcriptional 
regulation of metabolism in liver, we decided to further investigate its function by perturbing 
hepatocytes homeostasis by starvation [107]. 
 
 
Table 4 - Transcription factors identification for the tissue-specific metabolic pathways identified by DINA. List of transcription 
factors regulating the majority (i.e. 7 out of 9) of the tissue-specific metabolic pathways. In bold genes with know TF activity, in 
normal text genes encoding protein indirectly involved in transcription. The column citations contain works reporting the 
association of the transcription factor and metabolism. The column Role contains the function (activator or inhibitor) of the TF 
predicted by DINA. 
Gene Symbol Name Role Citations 
NR1H4 nuclear receptor subfamily 1, group H, member 4 activator [108-110] 
ESRRG estrogen-related receptor gamma activator [109, 111] 
TRPS1 trichorhinophalangeal syndrome I inhibitor  
NR1I3 nuclear receptor subfamily 1, group I, member 3 activator [109, 112, 113] 
HNF4A hepatocyte nuclear factor 4, alpha activator [109, 114] 
ZNF394 zinc finger protein 394 inhibitor  
TBR1 T-box, brain, 1 activator  
DAB2 disabled homolog 2 activator  
DIP2C disco-interacting protein 2 activator  
TRIM15 tripartite motif-containing 15 activator  
ASB9 ankyrin repeat and SOCS box-containing 9 activator  
YEATS2 YEATS domain containing 2 inhibitor  
SIRT4 sirtuin 4 activator [101-103] 
 
 
During starvation, a switch from anabolism to catabolism occurs: cells start to mobilize stored nutrients, 
such as glycogen and triglycerides, cell growth is arrested and autophagy is promoted [107, 115]. During 
starvation there are large changes in gene expression that affect specific metabolic pathways. For 
example, genes involved in fatty acid -oxidation are up-regulated [112] whereas genes involved in 
biosynthesis are down-regulated [116]. 
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In collaboration with Nicoletta Moretti at TIGEM (Naples, Italy), we performed a starvation time-course 
experiment for 8 hours in primary murine hepatocytes, by switching cells from a nutrient-rich medium 
to a starvation medium. Cells were collected at different time points during starvation (30 min, 1h, 2h, 
4h, 6h, 8h). Cells grown in nutrient-rich medium were used as control. We measured by quantitative 
real-time PCR (qRT-PCR) the variation in the expression level of Yeats2 in response to starvation in 
primary hepatocytes (Figure 22). As shown in Figure 22, Yeats2 seems to be an early response gene, 
quickly down-regulated upon starvation during the first two hours in primary hepatocytes. We also 
analysed the expression profiles of a subset of genes whose expression levels increase following 
starvation [112, 117]: Pgc1a, Acaa1a, Acot2, Cyp4a10, Cyp4a14, ApoA4 and Plin4 (Figure 22). 
These selected genes were up-regulated, as expected, during the first four hours of starvation, 
as shown in Figure 22: Pgc1a (Peroxisome  proliferator-activated receptor gamma, co-activator 1 alpha) 
encoding for a transcriptional co-activators that plays a key role in the regulation of both carbohydrate 
and lipid metabolism [Leone2005]; Acaa1a (Acetyl-CoA acyltransferase 1A) encoding a peroxisomal 
thiolase operating in catabolism of fatty acid [112] together with ACOT2 (Acyl-CoA thioesterase 2) which 
is localized in peroxisomes [118];  Cyp4a10 (Cytochrome P450, family 4, subfamily a, polypeptide 10) 
and  Cyp4a14  (Cytochrome P450, family 4,  subfamily a, polypeptide 14) encoding two members of 
Cytochrome P family able to oxidize a variety of structural compounds, as well as fatty acids [112, 119]. 
Genes involved in lipid transport showed an up-regulation as well, such as ApoA4 (Apolipoprotein A4), 
which enhances lipid absorption by promoting the assembly and secretion of Chylomicrons [112, 120]. 
In order to probe further the role of Yeats2 and its involvement in regulation of metabolism in 
liver, I analysed an existing in vivo time-series microarray experiment (ArrayExpress ID E-MEXP-748) 
from liver, muscle and adipose tissue of ApoE3Leiden transgenic mice, exhibiting a humanized lipid 
metabolism, treated with high-fat diet (HFD) for 0, 1, 6, 9, or 12 weeks [121].  Upon HFD feeding, genes 
involved in metabolic pathways, such as lipid metabolic processes, were found to be up-regulated in 
liver [121]. Based on these observations, we decided to investigate the expression of Yeats2 in this 
mouse model considering only the liver tissue, and we found that Yeats2 expression is strongly down-
regulated in HFD mouse liver (p-value of           ) [121, 122]. 
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Figure 22 - Yeats2 expression in hepatocyte cells during starvation. Real-time quantitative PCR measurements of the expression 
of Yeats2 and a set of marker genes at the indicated time-points following starvation. CRT indicates cell in rich medium. BF 
indicated the Bayes Factor estimated using BATS algorithm [123]. The gray area represents the standard deviation across the 
two bio-logical replicates. Gene expression was quantified using the ΔCT method with Gapdh used as normalization gene. 
(Figure taken from [68]) 
 
 
 
4.6 A web-tool implementing DINA 
I developed a web tool available at http://dina.tigem.it using Java Servlet Page (JSP) technology. The 
web-tool enables the user to query the 30 tissue specific networks with a set of genes gene in order to 
verify if the set is predicted to be tissue-specific or not in humans. As shown in Figure 23, the index page 
of the tool contains a text box in which the user can insert the gene list. As shown in Figure 24 the co-
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regulation probabilities across the 30 co-regulatory networks for the user’s gene list is reported in a 
resulting page using the radar-chart. Also the normalized entropy value (i.e.      ) of the pathway 
is reported in the result’s page. 
 
 
 
Figure 23 – Index page of DINA web tool. A User can insert his gene signature in order to evaluate if a gene signature is tissue 
specific or not. 
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Figure 24 – Page of the results for DINA web tool. The co-regulation probability across the 30 tissue specific co-regulatory 
network of the input gene signature is showed in radar-chart. 
 
 
4.7 Discussion and Conclusions 
In this chapter, I proposed a network-based approach (DINA) for the identification of condition specific 
pathways (or gene signatures). DINA is based on the hypothesis that genes belonging to a condition-
specific pathway are actively co-regulated only in specific conditions where the pathway is active, but 
not in others, independently of their absolute level of expression. DINA is based on an entropy-like 
measure and it is able to assess the specificity of a pathway by quantifying the variability in the co-
regulation probability of genes in the pathway across a set of condition-specific networks. Since DINA is 
based on detecting differences in the number of edges among genes in a pathway across a set of 
networks, it can be applied to any kind of network, independently of how this is generated. Differently 
from other available methods, DINA does not aim at identifying de-novo sub-networks of genes, but 
rather at identifying whether a known pathway (or a user’s gene signature) is differentially co-regulated 
across a set of conditions. 
Using thirty tissue-specific gene co-regulatory networks, I was able to show that DINA can be 
successfully applied to identify tissue-specific pathways. Indeed, as expected, several metabolic 
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pathways were predicted by DINA to be the most differentially regulated across the tissues and thus 
tissue-specific pathways specifically active in liver and kidney. Usually, tissue-specificity of a gene, or of a 
pathway, is assessed by quantifying the expression level of the genes in the concerned tissue [124]. 
However, observing gene expression only could be not sufficient, as in the case of metabolic pathways 
[125]. Here, I show that an alternative possibility is to check if the genes involved in the same pathway 
are specifically co-regulated in the concerned tissue. Of note, a similar approach has been successfully 
applied in yeast [126]. 
In this Chapter, I also proposed a method based on the Fisher's exact test to identify tissue-
specific Transcription Factors assuming that its tissue-specific targets tend to be co-regulated with it in a 
tissue-specific manner.  Hence, I tested this approach to identify regulators of tissue-specific metabolic 
pathways, and correctly identified Nuclear Receptors as their main regulators. With this method I was 
also able to identify a new putative tissue-specific negative regulator of hepatocyte metabolism Yeats2. 
Finally, I showed that DINA could be employed to analyse GEPs obtained during disease 
progression to make hypotheses on dysregulated pathways using as a study case a simplified model of 
hepatocellular carcinoma. It remains to be seen whether changes in signaling pathway activity can be 
detected using only a transcription based approach such as DINA. 
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Chapter 5 
A new differential multi information approach for the identification of PTMs 
5.1 A new method based on Differential Multi Information (DMI) 
Transcriptional regulations in a cell may be modulated at many different levels, such as transcription 
factor activation/deactivation by phosphorylation, or formation of active complexes with one or more 
cofactors. These modulators exert their function at the post-transcriptional/post-translational level, and 
therefore capturing this kind of regulatory interactions using transcriptional data, such as gene 
expression profiles (GEPs), is considered not possible. Recently, it has been shown that this is not the 
case, since fluctuations in the transcriptional level of modulators across different conditions can be 
exploited to infer post-translational regulation [65]. 
Our working hypothesis is the scenario in which a modulator (i.e. kinase/phosphatase) is 
expressed and activates a Transcription Factor (TF) (Figure 25B). As a result, the TF direct targets 
become co-regulated among them since they are all controlled by the same TF (Figure 25B). On the 
contrary, when the modulator M is not expressed, the TF is inactive and hence its targets are not co-
regulated. It is important to observe that our working hypothesis does not depend on changes in 
expression level of the target genes, but rather on changes in “co-regulation”. Indeed, as described in 
the previous chapters in the case of metabolic pathways, changes in co-regulation of the metabolic 
pathway enzymes are predictive of an active pathway, but their expression level does not change 
considerably among different tissues. Hence, the idea behind the method we developed consists of 
quantifying changes in co-regulation among a set of downstream targets        of the TF in presence 
(or absence) of a modulator . 
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Figure 25 – Hypothetical scenario in which a hypothetical Transcription Factor (TF) is activated by phosphorylation or de-
phosphorylation through a Modulator (M). G1, G2 and G3 are three downstream targets of the TF. (a) In absence of the 
Modulator (M) the downstream targets (G1, G2 and G3) are not co-regulated since the Transcription Factor (TF) is not active. 
(b) In presence of the Modulator (M) the downstream targets (G1, G2 and G3) become co-regulated through the active 
Transcription Factor (TF). 
 
 
This method requires a way to estimate the co-regulation among   variables, to this end I chose to 
compute the distance of their Joint Probability Density from the product of their Marginal Probabilities. 
This measure is known as the Multi-Information          of   random variables and is computed as 
the KL-Divergence       between their joint distribution and the product of their marginal. 
 
              || 
   ∫            
        
             
         
 
Where   is the joint distribution of the targets and    is the product of the marginal probabilities. 
      are random variables representing the gene expression level of targets        respectively. 
By this definition, the multi-information provides a measure of dependence among all the   variables 
and is non-negative because of the non-negativity of the   . 
Multi-Information can be also considered as a variant of the “Multivariate Mutual Information” 
as defined by McGill [127]. According to this definition, the Multivariate mutual information 
           between a joint random variable   and some label   is a Shannon Mutual Information 
but it measures only the interactions between the variables   that are dependent on  , discarding all 
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the other non-relevant intearctions. Multi-Information, instead, measures all the interactions among all 
the variables giving a completely different answer. The properties of the Multi-information are further 
discussed in [128]. 
In order to apply the Multi-Information measure to detect the modulator  of the    given its 
targets       , I developed the approach depicted in Figure 2. Specifically, I first discretize the 
expression of the modulator   in   bins and then compute the difference in Multi-Information (  ) 
among the targets in the bin where  is “High” and “Low” (Figure 26). Hence,    quantifies how much 
the modulator is able to influence the co-regulation of the targets of a given transcription factor. Since 
M is not known a-priori this approach is iterated for each of the modulator M to be tested and results 
are then ranked by    and by significance as detailed in 5.1.2. 
In order to discretize the expression of the modulator  , I decided to use the quantile 
discretization approach, in which each bin receives an equal number of data values and the data range 
of a bin varies according to the data values it contains. Specifically, each expression value of the 
modulator   is replaced by an integer value within the discrete interval         , where      is the 
total number of bins in which we wish to discretize the expression of . Each integer corresponds to the 
bin where the expression value falls into. Thus, samples whose expression values are replaced with the 
number 1 will be those where  is expressed at a low level, whereas samples whose expression values 
are replaced by the number      will be those where M is highly expressed [129, 130]. 
 
 
 
Figure 26 – For each step of the algorithm a candidate modulator M is tested. In the first step of the method the expression of 
the modulator M is discretized in   bins and the Differential Multi-Information      of the targets is computed always between  
the two bins where M expression is either “'High”' or “Low''. In the samples of “High” bin, the targets are strongly co-regulated, 
since they are controlled by the same transcription factor (activated by M). In the samples of the “Low” bin, the targets are not 
co-regulated since M is not able to activate the transcription factor. (a) Example of 2-bins discretization for the expression of M. 
(b) Example of 3-bins discretization for the expression of M. 
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The problem can be seen from a different point of view as the one of finding the modulator  that best 
partition the data in order to maximize the Multi-Information of the targets in the partition where  is 
“High”, and  at the same time minimize the Multi-Information in the other partition where  is “Low”.  
 
 
5.1.2 Significance estimation of DMI using permutation tests 
Since I cannot make any assumption regarding the probability distribution of the   , the only approach 
that I can use here is a permutation test in which we estimate the empirical distribution of   . 
Moreover, the value of multi-information is dependent on the number of variables among which we are 
estimating it, meaning that the same multi-information value computed among   and  variables (with 
   ) is not directly comparable. 
Hence, I proceeded as follows: first, I fixed a set of   target genes (i.e. variables) and a number 
of bins   to discretize the modulator M expression, I then computed the significance of a modulator  
by randomly selecting   genes in   number of trials, and each time I re-computed the    value thus 
generating its empirical distribution. The statistical power of the test is thus dependent of the 
parameter   whose upper bound is limited by the computational cost. Indeed the computational 
complexity of this permutation test is of the order             . It is obviously a function of the 
computational complexity of Multi-Information (  ) estimation algorithm (details in paragraph 5.2) that 
is itself function of the parameters   (number of genes) and   (number of samples used for its 
estimation). Considering that the permutation test must be executed for the upper and lower bin of 
each one of the   modulators to test, then the total computational complexity becomes       
         In the following tests, I decided to use L=1000 as a compromise between statistical power and 
computational cost. 
 
 
5.2 Rényi Multi-Information and its estimation  ̂  
In order to estimate the Multi-Information in each bin, I decided to use the Rényi Multi-Information 
(RMI). The RMI of   real-valued random variables           with joint density         and 
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marginal densities              is defined for any real parameter   assuming the underlying 
integrals exist [131]. For     Renyi multi-information is defined as: 
 
            
 
   
∫
  (     )
(∏       
 
   )
    ( 
    )
  
 
 
For     it is defined by the limit            . In fact, the classical multi-information is just special 
case of Rényi multi-information with    . 
 
Definition (generalized nearest-neighbor graph) [131]: Let   be a finite set of points in an Euclidean 
space    and let   be a finite non-empty set of positive integers. We define the generalized nearest-
neighbor graph        as a directed graph on  . The edge set of        contains for each     an 
edge from each vertex     to its  -th nearest neighbor. That is, if we sort 
    { }    {           | |  } according to the Euclidean distance to  :                       
   | |    then    is the  -th nearest-neighbor of   and for each     there is an edge from   to    in 
the graph.  
 
Definition (sum of the p-th powers of Euclidean lengths of its edges) [131]: Let   be a finite set of 
points in an Euclidean space    and let   be a finite non-empty set of positive integers. For     let us 
denote by       the sum of the  -th powers of Euclidean lengths of its edges. 
 
      ∑ ‖   ‖
 
              
 
 
where           denotes the edge set of        
 
We are now ready to present the estimator of Rényi Multi-Information based on the generalized 
nearest-neighbor graph and a copula transformation. For more details and the theorem demonstrations, 
please refer to [131]. 
Suppose we are given an i.i.d. sample              where each       
    
      
   has 
density         and marginal densities             . In [131] the authors showed that we 
can estimate the entropy      for         as: 
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with       equal to the sum of the p-th powers of Euclidian lengths of edges of the nearest-neighbor 
graph       for some finite non-empty    
  and with   representing a numeric constant dependent 
on           that can be estimated empirically from a large i.i.d. sample, as detailed in [131],. 
Finally, as described in [131], we can estimate the Rényi Multi-Information    by 
 
 ̂          ̂ ( ̂   ̂     ̂ ) 
 
where ̂  is defined as before and the sample ( ̂   ̂     ̂ )    ̂      ̂        ̂     .  ̂    is called 
empirical copula transformation [132] and basically consist into the following transformation where the 
j-th coordinate of  ̂  equals 
 
 ̂ 
  
 
 
       
     
    
      
    
 
where           is the number of elements of   less than or equal to  . 
The computational complexity      for the estimation of Rényi Multi-Information depends of 
the complexity of the K nearest-neighbors algorithm, which is linear in the number of point and the 
number of features for each point, and the complexity of copula transformation, which is quadratic in 
the number of point. Hence, the computational complexity for the estimation of Rényi Multi-
Information is: 
 
               
 
where   is the number of i.i.d. samples used for its estimation (i.e. number of experiments) and   is the 
number of features of each i.i.d sample (i.e. number of genes). 
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5.2.1 The rate of convergence of   ̂  
I tested the convergence of the estimated Rényi Multi-Information to the true value. I generated two 
dataset of 4000 i.i.d. samples from a multivariate Gaussian distribution of dimension 3 with 0 mean and 
an identity covariance matrix, corresponding to independent variables (    ) or a randomly chosen 
symmetric covariance matrix, corresponding to a     . Figure 27 show the estimation of  ̂  among 
the three variables in the case of dependent variables (i.e.     ) and its error. Figure 28 instead 
shows the estimation of  ̂  among the three variables in the case of independent variables (i.e.    ).  
 
 
 
 
Figure 27 -   ̂  for 3 variables as a function of the number of i.i.d used. The 3 variables are dependent variables. The estimation 
of  ̂  is computed 20 times for each point and its standard deviation is reported. (A) The convergence of  ̂  to the true value 
of   . (B) The error to estimate  ̂  as a function of the number of i.i.d. used. 
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Figure 28 -  ̂  among 3 variables as a function of the number of i.i.d used. The 3 variables are independent variables. The 
estimation of  ̂  is computed 20 times for each point and its standard deviation is reported. (A) The convergence of  ̂  to the 
true value of   . (B) The error to estimate  ̂  as a function of the number of i.i.d. used. 
 
 
5.3 Alternative approaches to identify post-translational modulators. 
The difference in Rényi Multi-Information (DMI) I described above is certainly not the only possible way 
to measure changes in the dependence among variables and hence to identify post-translational 
modulators of TF activity. Therefore in addition to DMI I also explored two alternative approaches to as 
detailed below.  
 
 
5.3.1 Multidimensional Independent Test (MIT) 
Since I am interested in detecting changes in co-regulation among the targets       of a TF due to a 
modulator , an alternative strategy is to use an independence test between the variable   
        and the variable           representing the modulators (i.e. here      ). 
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Formally, this is equivalent to consider a sample of       valued random vectors                 
with independent and identically distributed (i.i.d.) pairs defined on the same probability space and 
testing the null hypothesis (  ) that  and  are independent: 
 
                    
 
and possibly making minimal assumptions regarding the probability distributions. To test    we can use 
one of the two methods presented in [133]. The authors proposed two different approaches to test the 
independence between two multidimensional variables. The first method consists in partitioning the 
underlying space, and in evaluating a test statistics on the resulting discrete empirical measures. I did 
not test this method because of the computational complexity, which is exponential in the number of 
bins used for the discretization step elevated to the sum of the dimensions of the two variables to test. 
The method that I tested is the other method proposed by Gretton in [133], it is a kernel-density 
estimation test that is based on a cross-covariance operator and on reproducing kernel Hilbert space 
(RKHS).  
A possible limitation of this strategy (i.e. test only the independence between two 
multidimensional variables) consists in the fact that if the modulator M being tested is not a real 
modulator but instead it is a itself a target of the TF, then it will be strongly co-regulated with the targets 
G, and the method would detect a dependence between M and G, and hence M would be flagged as a 
modulator of the TF. This modulator however would obviously be a false positive. 
 
 
5.3.2 Conditional Multidimensional Independent Test (CMIT) 
Another possible approach could be of using the CMIT test described in [134]. Here, the authors present 
a new measure of conditional dependence among random variables, based on normalized cross-
covariance operators and on reproducing kernel Hilbert spaces. The proposed criterion does not depend 
on the choice of kernel in the limit of infinite data, for a wide class of kernels. At the same time, it has a 
straightforward empirical estimate with good convergence behaviour.  
The CMIT test applied to the problem of finding modulator M of a TF can be implemented as 
follows: given the target genes          of the transcription factors    and a modulators  , we 
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can test the conditional independence of   and   given  using the CMIT test,  thus solving the problem 
of finding the modulator for which the targets and the transcription factor(s) are co-regulated. 
In order to apply the CMIT test, we have to know which is the TF that regulates our targets (this 
condition is usually satisfied) but we also have to assume that the TF and targets are co-regulated and so 
statistically dependent, introducing others constraints in our model. 
 
 
5.4 Performance of DMI, MIT and CMIT on simulated datasets 
In the following section, I will illustrate the test I performed to assess the efficacy of the Differential 
Multi-Information (DMI) procedure I introduced in the previous sections. I will start with a definition of 
the performance measure I decided to use followed by a description of the datasets used for the test 
and the results I obtained. I also compared the performance of the DMI approach with other possible 
measures of dependence among n variables. 
 
 
5.4.1 PPV-Sensitivity Curve 
Positive Predicted Value (PPV) is defined as the fraction of predicted modulators (M) that are correctly 
identified by the algorithm, that is: 
 
    
  
     
 
where    are the true positive and    are the false positives. Sensitivity, instead, is defined as the 
fraction of all the true modulators that are retrieved by the algorithm: 
 
            
  
     
 
 
where    are the false negatives. Hence, a PPV-Sensitivity curve represents the Precision against the 
Sensitivity with the predictions of the algorithm ranked according to the value of   . 
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In order to assess the goodness of the performance, I also computed the expected performance of an 
algorithm that randomly choses modulators assuming a uniform probability distribution over the set 
modulators.  This means that: 
 
        
                   
                     
 
 
 
5.4.2 Generation of the “in silico” dataset 
I generated two datasets consisting of     simulated GEPs each. The list of the two “in-silico” datasets I 
generated and the parameters I used are reported in Table 5. The first dataset D1 consists of 60 genes, 
among which only 10 genes are assumed to be the known targets of the TF (i.e. are           ), 50 
genes are assumed to be possible modulators M of the TF, but only 20 of them are the true modulators. 
In addition I assumed that 10 of the remaining 30 false modulators are indeed unknown targets of the 
TF and hence co-regulated with the TF itself, thus making it harder for the methods to distinguish them 
from the true modulators.  
The second dataset D2 is constructed in a similar way but with a larger number of genes. 
Specifically D2 consists of 760 genes. As for dataset D1, only 10 genes are assumed to be the known 
targets of the TF (i.e. are          ), whereas the remaining 750 genes are assumed to be 
possible modulators M of the TF, with only 50 of them being the true modulators. 
In order to generate the 100 GEPs in each dataset I proceeded as follows. For clarity, I will 
describe only the generation of the D1 dataset, since the D2 dataset was generated in a similar manner. 
I divided the 100 GEPs in two subsets of 50 GEPs each: one subset in which the TF is active (hence the 
true modulators are expressed and the targets are co-regulated) and one in which the TF is inactive 
(hence the true modulators are not expressed and the targets are independent). In the first subset, I 
simulated the expression profiles of the 10 TF’s targets (known and unknown) using a multivariate 
Gaussian distribution with a covariance matrix with off-diagonal elements equal to      , mean equal 
to   and a random standard deviation in the interval        . In the second subset,   the expression 
values of the TF’s targets are sampled again from the same multivariate Gaussian distribution but with a 
diagonal covariance matrix (i.e. off-diagonal element are set to 0). The expression profiles of the 20 false 
modulators were generated using a normal distribution with mean   and random standard deviation in 
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the interval         in both the subsets. Finally, in order to simulate the expression profiles of the true 
modulators I followed this strategy: in the first subset (i.e the    samples where the targets are co-
regulated), I sampled from a normal distribution         (i.e. with average expression around 1), on 
the contrary in the second subset (i.e the    samples where the targets are independent), I used a 
normal distribution         (i.e. with average expression equal to 0).  
 
 
Table 5 - Description of the parameters used in each “in-silico” dataset. The column Dataset indicate the name of the dataset. 
The column   the strength of the dependence of the targets        . The column #Targets represents the number of targets 
of the TF used as input for the tested methods.  The column #True Mod. contains the number of modulators of the TF present 
in the dataset. The column #False Mod. contains the number of genes in the dataset that are not modulator of the TF. Finally, 
the column #Uknw. Targ. contains the number of unknown targets of the TF and hence co-regulated with the TF itself, thus 
making it harder for the methods to distinguish them from the true modulators (these are thus themselves false modulators). 
Dataset   #Targets #True Mod. #False Mod. #Uknw. Targ. 
D1 0.8 10 20 30 10 
D2 0.6 10 50 700 500 
 
 
 
5.4.3 Comparison of the “In-silico” performance of the different methods. 
I compared my method based on Differential Multi-Information with the other two algorithm presented 
in the previous sections. The DMI was applied as described in section 5.1 and 5.2 using a number of bin 
for discretization of the GEPs equal to 2 (unless specified). 
The PPV-sensitivity curve for the D1 dataset (Table 5) is reported in Figure 29 where the 
Differential Multi-Information (   ) method archive the best performance, ranking the    modulators in 
the top    positions. The results were ranked in descending order according to the value of the 
estimated    . We observe that when using the     method the value of the     for the false 
modulators is nearly   but it is very large for the true modulators. 
The results for the dataset D2 are reported in Figure 30 where the     method still achieves the 
best performance ranking the    true modulators in the top 50 positions. In this case as well the     of 
the true modulators is very large compared with the    of the false modulators that is close to  . 
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Figure 29 – PPV-sensitivity curve using the D1 dataset for 3 tested methods:    , MIT and CMIT. The     method achieves the 
best performance ranking the 20 real regulators in the top 20 positions. The random PPV value is also shown for comparison 
(black dotted line). 
 
 
 
Figure 30 - PPV-sensitivity curve using the D2 dataset for 3 tested methods:    , MIT and CMIT. The     method archives the 
maximal performance ranking the 50 real regulators in the top 50 positions. Also the random value has shown as comparison 
(black dotted line). 
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I also simulated 4 additional datasets with the same parameters of D2 (Table 5) but with different 
number of experiments in the two subsets (i.e. the one in which the targets are dependent and the one 
in which the targets are not). Specifically, in these 4 datasets the number of GEPs in the first subset, in 
which the TF’s targets are dependent, is either 30, 40, 60 or 70 out of 100 GEPs. The PPV-sensitivity 
curves for all the three methods applied to these 4 dataset are reported in Figure 31. Again the DMI 
method still achieves the best performance.  
 
 
 
Figure 31 – PPV-sensitivity curve using “in-silico” dataset D2 where the targets are dependent in the 30 (a), 40 (b), 60 (c) and 70 
(d) of the experiments. 
 
 
Finally, I also computed the p-value using the permutation test as described in the subsection 5.1.2. In 
this case I first applied a threshold of p<0.05 to deem a prediction as significant and then I ranked only 
the significant predictions according to     in descending order as before. The PPV-sensitivity curves are 
shown in Figure 32. In Table 6, I reported the Area Under the Curve computed from the PPV-sensitivity 
curves. For completeness I also repeated the DMI approach using three discretization bins rather then 2 
and reported the results in Table 2. 
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Figure 32 - PPV-sensitivity curve using “in-silico” dataset D2 where the targets are dependent in the 30 (a), 40 (b), 60 (c) and 70 
(d) out of the 100 GEPs. Only modulators with p-value = 0 have been selected. 
 
 
 
Table 6 – Area Under the Curve (AUC) of the PPV-sensitivity curves for the DMI method using the p-value to cut the results, 
with either 2 or 3 bins used for discretization of the GEPs according to the modulator expression level. 
Targets dependence AUC % 2 bins AUC % 3 bins 
30% 98.1% 100.0% 
40% 100.0% 98.8% 
60% 98.2% 92.4% 
70% 92.0% 64.0% 
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5.5 Discussion and Conclusions 
In this Chapter I presented and tested an original method based on Multi-Information to identify post-
translational “modulators” of a transcription factor from gene expression profiles. A modulator could be 
for example a kinase or phosphatase able to activate/deactivate the transcription factor.  This method is 
based on the estimation of multi-information among the targets of the transcription factor and it uses a 
permutation test to assess the significance of a possible modulator. Using an in-silico dataset, I 
evaluated and compared the performance of the proposed method. 
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Chapter 6 
Evaluation of the DMI method  
 
This chapter describes the evaluation of the DMI method using real experimental datasets. The chapter 
begins with a brief description of the experimental dataset, then continues with the presentation of the 
results obtained by testing the performance of DMI method on a set of transcription factors of interest, 
including a brief description of each of them. 
6.1 Description of the experimental dataset 
As presented in the Chapter 5, the DMI method requires in input a list of targets G of a TF, a set of Gene 
Expression Profiles (GEPs) and a list of possible modulators M to test. In order to evaluate the 
performance of DMI when applied to real experimental data, I chose 7 Transcription Factors, with 
known transcriptional targets, as listed in  
Table 7, and whose activity is regulated by a set of well-characterised kinases. For each TF I first 
collected its known targets (as detailed in the following sections), I then retrieved the kinases 
modulating the TF activity from PhosphoPOINT [135] and BioGrid [136] databases. I thus obtained a 
“Golden Standard” for each TF consisting of experimentally verified kinases.  
I then exploited this Golden Standard to assess the performance of the DMI method in correctly 
identifying the modulators each of the TF. To this end, I applied DMI to a compendium  of 5,372 high 
quality human GEPs representing 369 different cell and tissue types, disease states and cell lines, 
described in [137]. GEPs were measured using the Affymetrix HG-U133A platform and normalized using 
the Robust Multi-array Average (RMA) normalization as implemented in the R package Bioconductor 
[72].  
As list of possible modulators M, I collected the 491 kinases present on HG-U133A platform and 
associated the Gene Ontology (GO) molecular function term “protein kinase activity”.  
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Table 7 – List of the 7 transcription factors tested including their official gene symbol and their full name. 
Gene Symbol Name 
TP53 tumor protein p53 
MYC myelocytomatosis oncogene 
STAT3 signal transducer and activator of transcription 3 
SMAD3 SMAD family member 3 
GATA2 GATA-binding protein 2 
ELK1 ETS domain-containing protein Elk-1 
ETS1 v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) 
 
 
6.2  Identification of kinases regulating P53 
P53 protein is a tumor suppressor Transcription Factor protein encoded by TP53 gene located on the 
short arm of chromosome 17 (17p13.1). Since it was discovered 30 years ago [115] as a cellular partner 
of SV40 Large Tumor Antigen, the oncoprotein of this tumor virus, more than 50,000 PubMed-listed 
publications have been written on it. The notion of pivotal tumor suppressor and the fact that it 
constitutes a natural anti-cancer defense for our body have attracted a lot of interest in the study of this 
gene. Disrupting of TP53 functions leads to reduced tumor suppression, indeed more than 50% of 
human tumors contain a mutation or deletion of the TP53 gene [138]. 
The protective function carried out by the P53 protein is achieved through several different 
mechanisms including regulation of apoptosis, genomic stability, and inhibition of angiogenesis. When 
the DNA has sustained damage, P53 transcribes a set of genes whose protein products are responsible 
for DNA repair. To perform this task, P53 can also induce growth arrest by halting the cell cycle for long 
enough to allow DNA repair. If the DNA cannot be repaired, an apoptosis program is initiated to 
eliminate the DNA-damaged cell [115]. 
One of the main open challenges in p53 biology is to understand how p53 is able to discriminate 
which targets must be activated or repressed to obtain a specific cellular outcome (repair verus 
apoptosis). In the recent years different models have been proposed.  For example, some researchers 
suggested that apoptosis is triggered only when the amount of active P53 protein present in a cell 
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reaches a threshold level [139].  Another model is one in which P53 target gene selection is determined 
mainly by co-factors, P53-binding factors and post-translational modifications [140].  
 
 
 
Figure 33 - 3D structure of P53 human protein (source Wikipedia) 
 
 
A lot is known on how P53 activity is tightly regulated in the cell by co-factors [141] as well as post-
translational modifications [142]. Several Serine and Threonine sites in the P53 protein are targeted for 
phosphorylation in response to a myriad of stress types, which include, but are not limited to, DNA 
damage, oxidative stress, osmotic shock and ribonucleotide depletion.  
In order to test the performance of DMI in identifying kinases regulating P53 activity, I selected a 
set of 34 bona fide transcriptional (Table 8) targets reported in [94]. I also identified 69 kinases known to 
interact with P53 protein (Table 8) as described in section 6.1. I then applied DMI on the set of 5,372 
GEPs and tested each of the 491 kinases using a different discretization bins and with or without 
permutation tests using 1000 permutations. 
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Table 8 – List of 34 bona fide targets used as input for our method and list of know kinases interact with P53 protein used as a 
golden standard. 
P53 OFFICIAL GENE SYMBOLS 
TARGETS BDKRB2, BTG2, CCNG1, CD82, CDC25C, CDKN1A, CRYZ, CTSD, CX3CL1, DKK1, EGFR, FAS, 
GADD45A, GML, HGF, IER3, IGFBP3, MDM2, MET, MMP2, ODC1, PCBP4, PLK2, RB1, 
S100A2, SCARA3, SCD, SERPINE1, SFN, SLC38A2, TAP1, TGFA, THBS2, TP53I3 
KINASES ABL1,ALK,ATM,ATR,AURKA,AURKB,BCR,BMX,CCNH,CDK1,CDK2,CDK5,CDK8,CDK9,CDKN1A,
CHEK1,CHEK2,CSNK1A1,CSNK1D,CSNK1E,CSNK1G1,CSNK1G2,CSNK1G3,CSNK2A1,CSNK2A2,
CSNK2B,DAPK1,DAPK3,EIF2AK2,EPHA3,ERBB4,ERCC2,ERCC3,GSK3A,GSK3B,GTF2H1,HIPK1,
HIPK2,HIPK3,IGF1R,IKBKB,LYN,MAP3K1,MAPK1,MAPK10,MAPK14,MAPK3,MAPK8,MAPK9,
MNAT1,PLK1,PLK3,PPP4C,PRKCA,PRKCD,PRKD1,PRKDC,PTK2,RYK,SMG1,STK11,STK4,TAF1,T
RIM24,TRIM27,TRIM28,TTK,VRK1,VRK2 
 
 
 
The resulting PPV-Sensitivity curves are reported in Figure 34, with the performances of a random 
algorithm shown for comparison. As shown in from Figure 34 the best number of bins to use for the 
discretization step seems to be 3, where we achieve the best performance with an Area Under the Curve 
(AUC) of about 27.2% (Table 9) using the p-value. 
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Figure 34 – PPV sensitivity curve and relative Area Under the Curve (AUC) for the identification of post-translational modulators 
of P53 using different number of bins for the expression discretization of the modulator. Red dotted line represents the 
performance of a random algorithm. (a) 3 bin discretization. (b) 5 bin discretization. (c) 7 bin discretization. (d) 10 bin 
discretization. 
 
 
Table 9 - Area Under the Curves (AUC) of PPV-Sensitivity for the identification of post-translational modulators of the P53 
transcription factor. AUC (   rank) column is the AUC of the PPV-sensitivity curve using only the    values to rank the 
modulators. AUC (pval) column is the AUC of the PPV-sensitivity curve removing the non-significant values of    using the p-
value. AUC_norm (pval) column is the normalized value of the AUC respect to the maximal value it can achieve:   
                , where                  is the maximal sensitivity can be achieved after removing non-significant 
values. In bold the best AUC for the different discretization strategies. 
Disc. Type AUC (   rank) AUC (pval) AUC_norm (pval) 
3 bins 21.7% 17.7% 27.2% 
5 bins 19.2% 15.5 % 21.4% 
7 bins 18.3% 14.2% 22.8% 
10 bins 17.0% 11.3% 19.5% 
 
 
93 
 
6.3 Identification of kinases regulating  MYC 
MYC is probably the most important and studied oncogene with more than 19,000 PubMed publications 
associated to it. MYC protein belongs to the family of transcription factors containing bHLH/LZ (basic 
Helix-Loop-Helix Leucine Zipper) domain. MYC protein, through its bHLH domain can bind to DNA, while 
the leucine zipper domain allows the dimerization with its partner MAX, another bHLH transcription 
factor. 
 
 
 
Figure 35 - 3D structure of MYC human protein (source Wikipedia). 
 
 
 
When it was discovered about 25 years ago, it changed the definition of oncogene [143]. Before MYC, 
oncogenes gain-of-function was considered to be caused only by somatic mutations in their coding 
sequence. With MYC new mechanisms of oncogenes activation, including gene amplification, 
chromosomal activation and insertional mutagenesis have been discovered. With the discovery of MYC, 
probably, the most important breakthrough was the comprehension that MYC dysregulation is not due 
only to mutations and rearrangements of the MYC genomic locus, but also to dysregulation of the 
control mechanisms targeting its expression. Indeed MYC expression is tightly controlled in cell. Several 
efforts have been directed in understanding what is the normal expression pattern of MYC and how its 
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expression is regulated. MYC was identified as the first eukaryotic cellular gene to be regulated by 
transcription elongation control [144-147] and loss of this control is evident in cancer. Different studies 
in mouse models have revealed that abnormalities through direct or indirect mechanisms affecting MYC 
mRNA expression are able to drive cancer development [148, 149]. Regarding post-translational control, 
phosphopeptide analysis revealed that specific serine and threonine residues of MYC are 
phosphorylated in vivo [150]. Amati and colleagues showed that MYC–MAX heterodimerization is 
essential for MYC transformation [151].  
Recent studies based on chromatin immunoprecipitation assays (ChIP) have helped researchers 
to better identify MYC transcriptipnal targets. In particular these studies have demonstrated that MYC 
can be considered as a “global transcriptional regulator”, since it is able to bind approximately 10-15% 
both coding and no-coding regions of the genome [152, 153]. Multiple pathways are regulated by MYC 
in order to drive any one of a plethora of biological programmes, including cell proliferation [150] and 
cell differentiation [154-158].  
I conclude this brief overview of MYC by quoting [143]: “MYC is downstream of many signal 
transduction pathways, functioning as a central hub that integrates multiple intracellular and 
extracellular cues. MYC then processes and interprets these instructions, much like the central 
processing unit of a computer”. 
In order to apply the DMI method to identify kinases regulating MYC activity, I retrieved 68 
experimentally verified MYC transcriptipnal targets (Table 10) from the Myc target gene database [159]. 
The “Golden Standard” contains 59 know kinases (Table 10) interacting with MYC protein and generated 
as described in section 6.1. 
 
 
Table 10 - List of 68 experimentally verified targets of MYC and know kinases interact with MYC protein used as a golden 
standard. 
MYC OFFICIAL GENE SYMBOLS 
TARGETS ACP5, AKAP1, APEX1, APP, ARPC4, BAX, BCAT1, CCKBR, CDC25C, CDKN1B, CKS2, CSTB, 
CTSC, DDX10, DDX18, DDX5, DKC1, EIF2S1, EIF4A1, ENO1, FASN, H2AFZ, HMOX1, HSPE1, 
ID3, IMPA2, LAMB2, LAMP1, MAT2A, MSH2, MSN, NAP1L1, NPM1, ODC1, PA2G4, PCNA, 
PHB, POLD2, PPAT, PPIA, PPID, PREP, PRPS2, PSMB1, PTPN1, PYCR1, RARA, RPL10, RPL13, 
RPL22, RPL27, RPL5, RPS16, RPS19, RPS20, RPS5, SERPINE1, SHMT1, SNRPD3, SRM, TERT, 
TFRC, TGFB1, TOP1, TP53, TXN, UCHL1, VHL 
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KINASES ADRBK2, ALPK1, BCR, BMPR1A, BTK, CAMK1G, CAMK2G, CCNH, CDK12, CDK2, CDK4, CDK8, 
CDK9, CSNK1E, CSNK2A1, CSNK2A2, ERCC3, GRK1, GSK3A, GSK3B, HCK, IGF2R, IKBKAP, 
IRAK1, LATS1, LIMK2, MAP2K1, MAP2K3, MAP2K7, MAP3K13, MAPK1, MAPK3, MAPK7, 
MAPK8, MATK, MYLK, NEK2, NEK9, NTRK1, PAK6, PBK, PDK1, PIM1, PKN1, PLK1, POLR2B, 
POLR2E, POLR2I, PRKDC, RAF1, SPEG, SQSTM1, TIE1, TRIB1, TRIM28, TXK, WEE1, WNK1, 
YES1 
 
 
 
As in the case of p53, I applied DMI to the set of 5,372 GEPs using the list of targets listed in Table 4 and 
tested each of the 491 kinases using a different number of discretization bins and with or without 
permutation tests using 1000 permutations. The resulting PPV-Sensitivity curves for the identification of 
the kinases regulating MYC are reported in Figure 36. Also the performances of a random algorithm is 
shown for comparison. 
In this case the AUC is lower than in the case of p53, however also in this case the best number 
of bins to use for the discretisaiton seems to be three, even if the AUC is low in this case, nevertheless 
the PPV achieve its maximum with three bins (Figure 4A). The AUCs for all the PPV-sensitivity curves are 
reported in Table 11. 
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Figure 36 – PPV-sensitivity curve and relative Area Under the Curve (AUC) for the identification of post-translational modulators 
of MYC using different number of bins for the discretization of the modulator expression. Red dotted line represents the 
performance of a random algorithm. (a) 3 bin discretization. (b) 5 bin discretization. (c) 7 bin discretization. (d) 10 bin 
discretization. 
 
 
Table 11 - Area Under the Curves (AUC) of PPV-Sensitivity for the identification of post-translational modulators of the P53 
transcription factor. AUC (   rank) column is the AUC of the PPV-sensitivity curve using only the    values to rank the 
modulators. AUC (pval) column is the AUC of the PPV-sensitivity curve removing the non-significant values of    using the p-
value. AUC_norm (pval) column is the normalized value of the AUC respect to the maximal value it can achieve:   
                , where                  is the maximal sensitivity can be achieved after removing non-significant 
values. In bold the best AUC for the different discretization strategies. 
Disc. Type AUC (   rank) AUC (pval) AUC_norm (pval) 
3 bins 12.9% 6.4% 13.5% 
5 bins 13.4% 6.8% 15.5% 
7 bins 14.0% 7.3% 17.4% 
10 bins 14.6% 7.4% 19.0% 
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6.4 Identification of kinases regulating STAT3 
Signal transducer and activator of transcription 3 (STAT3) is a transcription factor which in humans is 
encoded by the STAT3 gene. STAT3 protein belongs to the family of STAT protein, a family of proteins 
usually phosphorylated by receptor-associated kinases. Characteristic of this family proteins is that 
when phosphorylated they form homo or heterodimers that translocate to the nucleus, where they act 
as transcription activators. STAT3 is the major member of STAT family consisting of STAT1, STAT2, 
STAT3, STAT4, STAT5α, STAT5β, and STAT6, plays important roles in cell differentiation and proliferation. 
In a variety of human cancers, constitutive activation of STAT3 is sufficient to induce tumor formation 
[160, 161]. 
I collected 10 bona fide targets of STAT3 combining expression data and ChIp data from two 
different studies [162, 163]. I selected the 10 genes identified in common in both studies. Known kinases 
regulating STAT3 activity were collected as described before for a total of 40 kinases. 
 
 
 
 
Table 12 - List of 10 “bona fide” collected targets of STAT3 and the 40 known kinases interacting with STAT3 protein used as a 
golden standard 
STAT3 OFFICIAL GENE SYMBOLS 
TARGETS ABCA1, ADM, BCL6, CEACAM1, CXCL2, OAS2, OASL, SERPINA3, SERPINB3, SERPINE2 
KINASES ALK, BMX, CCND1, CDK9, CDKN1A, EGFR, EIF2AK2, EPHA5, ERBB2, FER, FES, FGFR1, FGFR2, 
FGFR3, FGFR4, FLT1, HCK, IGF1R, IRAK1, JAK1, JAK2, JAK3, LCK, MAP3K7, MAPK1, MAPK3, 
MAPK8, MET, MTOR, NLK, PDGFRA, PDGFRB, PRKCD, PRKCZ, PTK2, PTK2B, RET, RPS6KA5, 
SRC, SYK 
 
 
PPV-Sensitivity curves for the identification of the kinases regulating MYC are reported in Figure 37. Also 
the performances of a random algorithm are showed as a comparison. 
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Figure 37 - PPV-sensitivity curve and relative Area Under the Curve (AUC) for the identification of post-translational modulators 
of STAT3 using different number of bins for the discretization of the modulator expression. Red dotted line represents the 
performance of a random algorithm. (a) 3 bin discretization. (b) 5 bin discretization. (c) 7 bin discretization. (d) 10 bin 
discretization. 
 
 
Table 13 - Area Under the Curves (AUC) of PPV-Sensitivity for the identification of post-translational modulators of the P53 
transcription factor. AUC (   rank) column is the AUC of the PPV-sensitivity curve using only the    values to rank the 
modulators. AUC (pval) column is the AUC of the PPV-sensitivity curve removing the non-significant values of    using the p-
value. AUC_norm (pval) column is the normalized value of the AUC respect to the maximal value it can achieve:   
                , where                  is the maximal sensitivity can be achieved after removing non-significant 
values. In bold the best AUC for the different discretization strategies. 
Disc. Type AUC (   rank) AUC (pval) AUC_norm (pval) 
3 bins 9.6% 4.2% 11.9% 
5 bins 9.3% 5.3% 11.8% 
7 bins 10.6% 6.2% 14.5% 
10 bins 11.2% 8.9% 16.8% 
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6.5 DMI performance on additional transcription factors. 
As discussed in the Chapter 5, the DMI method requires as input a list of target genes of a TF, a set of 
Gene Expression Profiles (GEPs) and a list of possible modulators to test. 
In order to test the performance of DMI on additional transcription factors, I selected four 
transcription factors (Table 14) and their putative targets by combining data from MsigDb [164] and 
Chip [163] databases that are known to be regulated through post-translational mechanisms. 
 
 
Table 14 – List of the four transcription factors selected to test the DMI method. The columns report the official gene symbol, 
the name, the number of gene targets used as input for DMI and the number of kinases known to modulate the TF. 
Gene Symbol Name # of Targ. # of Kin. 
SMAD3 SMAD family member 3 43 26 
GATA2 GATA-binding protein 2 14 2 
ELK1 ETS domain-containing protein Elk-1 177 10 
ETS1 v-ets erythroblastosis virus E26 oncogene homolog 1 (avian) 12 6 
 
 
 
SMAD3 is a member of the SMAD family proteins belonging to the transforming growth factor 
beta (TGF-β) superfamily of modulators [165]. One of the first observations showing SMAD proteins at 
downstream of TGF-β pathway was the capability of SMAD proteins to accumulate in the nucleus in 
response to TGFβ or BMP [166, 167]. SMAD proteins undergo a constant process of nucleocytoplasmic 
shuttling mediated by phosphorylation [168, 169] and dephosphorylation [170] events. 
GATA2 is a member of GATA family of transcription factors, a family of evolutionarily conserved 
proteins playing a crucial role in the development and differentiation of eukaryotic organisms expressed 
particularly in hematopoietic cell lineages [171]. There are several studies on the characteristics and 
functions of the principal member (GATA1) of this transcription factor family, instead little is known 
about GATA2 [172]. Variations in the transcriptional activity of GATA2 transcription factor are also 
modulated by post-translational modifications [173] affecting nuclear localization, DNA-binding, protein 
stability, and/or cofactor recruitment. 
ELK1 is transcription factor member of the ETS family and of the ternary complex factor (TCF) 
subfamily. ELK1 seems play in many contexts [174], including long-term memory formation, drug 
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addiction, Alzheimer's disease, Down syndrome, breast cancer, and depression. The protein activity of 
ELK1 is strictly modulated through post-translational mechanisms. For example, it is activated by 
phosphorylation by three classes of MAP kinases, ERK, JNK, and p38 [175, 176] and it is repressed 
through dephosphorylation by the Protein phosphatase 2B (PP2B) [177, 178]. 
Also the ETS1 proto-oncoprotein [179] is a member of the ETS family of transcription factors. 
The DNA binding activity of ETS1 is tightly modulated by kinases and transcription factors [179]. ETS1 is 
expressed by many cell types and in hematopoietic cells it is involved in the regulation of cellular 
differentiation. 
PPV-Sensitivity curves for the identification of the kinases regulating these four transcription 
factors using the 3 bins discretization strategy are reported in Figure 38, while their AUCs are reported 
in Table 15. In Figure 38, also the performances of a random algorithm are showed as a comparison. 
 
 
Table 15 – Area Under the Curves (AUC) of PPV-Sensitivity for the identification of post-translational modulators of the P53 
transcription factor. AUC (   rank) column is the AUC of the PPV-sensitivity curve using only the    values to rank the 
modulators. AUC (pval) column is the AUC of the PPV-sensitivity curve removing the non-significant values of    using the p-
value. AUC_norm (pval) column is the normalized value of the AUC respect to the maximal value it can achieve:   
                , where                  is the maximal sensitivity can be achieved after removing non-significant 
values. In bold the best AUC for the different discretization strategies. 
Name AUC (   rank) AUC (pval) AUC_norm (pval) 
SMAD3 12.2% 7.3% 15.9% 
GATA2 6.5 6.5 6.5 
ELK1 11.5% 11% 13.6% 
ETS1 6.8% 5.4 11% 
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Figure 38 – PPV-sensitivity curve for the 4 transcription factors SMAD3, GATA2 ELK1 and ETS1 and in parentheses the 
number of know kinases interacting with them present in the “Golden Standard”.  
 
 
6.6 Discussion and Conclusions 
In this Chapter, I tested the DMI method on a set of transcription factors for which I was able to collect a 
bona fide set of targets and a set of known kinases regulating their activity to be used as a “Golden 
Standard”. I computed for each one of the collected transcription factors, the PPV-sensitivity curve using 
as the “Golden Standard” obtained by mining PhosphoPOINT and BioGrid databases containing 
experimentally verified protein interactions. It is important to remember that it is not possible have a 
complete “Golden Standard” containing all of the real modulators for a transcription factor of interest, 
because of the partial knowledge inherent in biology. Nevertheless, in these tests the method 
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performed very well achieving a high precision in all of the tests (Table 9, Table 11, Table 13 and Table 
15).  
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Chapter 7 
A case of study: Identification of TFEB modulators 
In this Chapter, I tested the DMI algorithm presented in the Chapter 5 and 6 for the 
identification of phosphatases interacting with the TFEB transcription factor. The Chapter starts 
with a brief introduction to TFEB biology, followed by an overview of High Content Screening 
(HCS) for the identification of modulators of a transcription factor of interest. I then discuss the 
application of DMI to this case study and the comparison of predicted modulators using the 
DMI computational approach with the results obtained using HCS.  
 
7.1 Introduction to TFEB 
Lysosomes are membrane-delimited organelles present in all mammalian cells except red blood cells. 
They are engaged in the degradation of macromolecules delivered from the cells own cytoplasm 
(autophagy) as well as materials taken up from the extracellular space. Malfunctions in lysosomes lead 
to Lysosomal Storage Disorders (LSDs) a class of diseases characterized by the progressive accumulation 
of undigested macromolecules in the cell, resulting in cellular dysfunction that leads to diverse 
pathological manifestations [180]. 
Transcription factor EB is a protein that in humans is encoded by the TFEB gene. TFEB belong to 
members of the microphthalmia–transcription factor E (MiT/TFE). TFEB is latent cytoplasmic 
transcription factor. Its inactive form resides in the cytoplasm (Figure 39), and when activated, it is 
translocated into the nucleus where it is able to active its target genes [181]. In the 2009 Sardiello et al. 
[181] showed the association of TFEB with lysosomal biogenesis and an increment of the degradation of 
complex molecules when this transcription factor is overexpressed, introducing for the first time the 
biological and medical importance of TFEB for its potential therapeutic involvement in Lysosomal 
Storage Disorders. 
In the 2011 Settembre et. al. [182] demonstrated a link between TFEB and autophagy pathway 
during starvation, also proving that TFEB nuclear translocation is induced by MAPK1 kinase 
phosphorylation. The authors proved that in order to be translocated into the nucleus, TFEB needs the 
addition of a phosphate group on one of its three serine sites Ser142, Ser332 or Ser402, indirectly showing 
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the existence of a phosphatase able to block TFEB into the cytoplasm removing the phosphate group 
from one of the three serine sites previously identified. 
 
 
 
Figure 39 – TFEB is a latent cytoplasmic transcription factor, its inactive form resides into the nucleus. When it is activated it is 
translocated into the nucleus and it is able to activate its downstream lysosomal targets. 
 
 
7.2 Introduction to High Content Screening 
In the last two decades, different high-throughput technologies to investigate molecular pathways and 
drug mode of action have been developed. In the study of the transcriptome, for example, two of these 
technologies such as oligo-based microarrays and Next Generation Sequencing method for 
mRNAs/microRNAs (RNA-sequencing) had a huge impact. At the same time, high-throughput 
technologies for the direct study of cellular behavior, including change in morphology or 
macromolecules localization, have been an open challenge due to incompatibility of the required 
techniques with high-throughput strategies. Recently, hardware improvements in microscopy, as well as 
auto-focusing and automatic sampe handling with dedicated robots, have led to the development of 
automated microscopes. These microscopy improvements combined with quantitative measurements 
from acquired images of fluorescence, morphology or macromolecules localization, have given rise to 
the new concept of High Content Screening (HCS). HCS can be considered a high-throughput technology 
based on automated imaging approach to measure individual cell spatio-temporal events in biological 
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systems, such as, organelle morphology and complex phenotypes. HCS provides the opportunity to 
measure cell sub-populations and to combine multiple measurements per cell. 
In high content screening cells are treated with drugs or via transfection of siRNA oligomers 
(RNAi) to study their effect on a phenotype of interest. Structures and molecular components of single 
cells are automatically analyzed (Figure 40). A common approach consists in using a florescent marker to 
measure changes in cell phenotype using automated image analysis. Through the use of fluorescent tags 
with different absorption and emission maxima, it is possible to measure several different cell 
components in parallel. Moreover, the image analysis techniques are able to detect changes at a 
subcellular level, including the translocation of a protein from an organelle to another, as well as, the 
translocation of a transcription factor from the cytoplasm to the nucleus. With this new high-throughput 
technology a large number of data points can be measured and animalized per cell. 
 
 
 
 
Figure 40 – Steps used in the high content screening experiments. First cells are treated, and then using confocal microscope 
connected to a pc images are automatically acquired. Finally quantitative measures are automatically extracted from image. 
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HCS has been successfully implemented in drug discovery [183] to identify small molecules, including 
peptides or siRNAs, able to modify the phenotype of a cell in the desired manner. A detailed guide for 
the use and applications of high contents screening can be found here [184]. 
 
 
 
7.3 Identification of kinases and phosphatases regulating TFEB 
As introduced in the section 7.1, TFEB translocation into the nucleus is regulated at a post-translational 
level by MAPK1 kinase [182], while the opposite mechanism allowing the export from the nucleus into 
the cytoplasm still remains unknown. We used the DMI method to identify phosphatases able to 
modulate the activity of TFEB by blocking it into the cytoplasm (or exporting from the nucleus) by  
removing the phosphate group on one of its three serine sites Ser142, Ser332 or Ser402 used by MAPK1. For 
this reason, I compiled a list of all the known 174 phosphatases present in the human genome to test 
them with DMA to identify the possible modulators of TFEB activity. I used as input for DMI 22 
experimentally verified lysosomal target of TFEB and the previously describes set of 5372 GEPs [181] 
(Table 16). 
 
 
 
Table 16 - List of 22 experimentally verified lysosomal targets of TFEB. 
TFEB OFFICIAL GENE SYMBOLS 
TARGETS ARSA, ARSB, ATP6V0E1, ATP6V1H, CLCN7, CTSA, CTSB, CTSD, CTSF, GALNS, GLA, GNS, GRN, 
HEXA, LAMP1, MCOLN1, NAGLU, NEU1, PSAP, SCPEP1, SGSH, TPP1 
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7.4 Comparison with High Content Screening results 
HCS has been used in our institute by Dr Diego Medina in order to identify possible phosphatases able to 
block the translocation of TFEB into the nucleus. This was achieved by setting up a high-content-
screening experiment using a library of siRNA oligos directed against 231 human phosphatases. The 
screening was performed in three nutrient conditions including, normal medium used as control, serum 
starvation and aminoacids starvation plus refeeding, to test TFEB translocation (starvation cause TFEB to 
translocate to the nucleus). The readout of these assays was the nuclear translocation of TFEB. We used 
the list of identified phosphatases from the first screening as a golden standard for our method. 
Specifically, we considered only the top six common phosphatases between the two conditions. The 
PPV-sensitivity curve is reported in Figure 41. 
 
 
 
 
Figure 41 – PPV-sensitivity curve for the identification of TFEB phosphatase modulators, using as a golden standard six 
phosphatases identified using the High Content Screening approach. P-value has been computed performing 1000 permutation 
tests. 
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These results underline the possibility to use our method combined with high content screening to 
reduce false positives discovery rate of modulators for a transcription factor of interest. 
 
 
7.5 Discussion and Conclusions 
As a case of study, in collaboration with Diego Medina and Adrea Ballabio at Telethon Institute of 
Genetics and Medicine (TIGEM), I tested the DMI method I developed for the identification of post-
translational modulators of a transcription factor on a TF of interest in my institute. TFEB is a latent 
cytoplasmic transcription factor and thus seems to be a perfect case of study. Comparing the results of 
DMI with a completely full biological approach such as High Content Screening, a very high PPV is 
achieved. These results confirm that DMI method could be instrumental in identifying post-translational 
regulatory interactions in an efficient and cost-effective manner. Moreover this method, combined with 
high content screening, could be useful to reduce false positives discovery rate in the identification of 
post-translation modulator for a TF of interest. 
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